Hybrid catheter for vascular intervention

Information

  • Patent Grant
  • 12042223
  • Patent Number
    12,042,223
  • Date Filed
    Thursday, September 8, 2022
    2 years ago
  • Date Issued
    Tuesday, July 23, 2024
    4 months ago
Abstract
A catheter for debulking of an undesired deposit from an inner surface of at least one of a blood vessel wall and a stent located in a blood vessel, the catheter having a tip section comprising: circumferentially-directed laser optics; and a circular-action cutter, wherein said circumferentially-directed laser optics is configured to transmit laser radiation for modifying an area of the undesired deposit thereby preparing said area for penetration of said cutter, wherein said cutter is configured to cut through said modified area and thereby debulk at least a part of the undesired deposit. In addition, a catheter for pacemaker and ICD (Implantable Cardioverter Defibrillator) lead extraction is disclosed.
Description
FIELD OF THE INVENTION

The invention relates to a hybrid catheter for vascular or other interventions.


BACKGROUND OF THE INVENTION

Peripheral and arterial vascular diseases are a common problem which may directly lead to morbidity and death. In the U.S. alone it is estimated that over 4 million people suffer from peripheral artery disease which, in severe cases, is treated with surgery or even amputation.


Flat lesions represent a significant challenge in gastroenterology. Removing of sessile and flat polyps, which may be associated with high risk for malignancy, requires, in most cases, usage of different techniques than those used for removing common polyps. These techniques may lead to the referral of patients to surgery instead of removal by the gastroenterologist. Other challenging lesions are nonpolypoid colorectal neoplasms (NP-CRNs). Barrett's esophagus is another common chronic condition. The prevalence in the U.S. population is estimated to be in the range of 1-2% of the adult population. Barrett's esophagus condition may lead to violent esophageal cancer, which is said to result in over 12,000 deaths per year in the U.S. alone and around 100,000 in China.


Laser and Mechanical Based Solutions for Angioplasty, Atherectomy and Thrombectomy:


The current state of the art in laser ablation technology for vascular intervention is based on use of an Excimer lasers with dedicated catheters such as Spectranetics' CVX-300® laser and TURBO-Booster® catheter. These technologies are described, for example, in U.S. Pat. Nos. 6,673,064, 7,811,281 and 7,572,254. Due to technical and safety considerations, the excimer laser used, generally, is often a Xenon Chloride laser operative at 308 nm with pulse widths in the range of 100 nanoseconds. These technologies are not ideal and have some limitations. For example, when dealing with heavy calcified plaques, there is a risk of perforation and damage from debris/plaque fragments. Therefore, the procedure requires a complex, large and costly system and the length of the procedure is quite significant in a manner that seems to limit its wide clinical utility. In addition, the technique had difficulties in treatment of large vessels such as SFA (Superficial Femoral Artery) which is very important in management of peripheral artery disease (PAD) wherein vessels larger than 4-5 mm in diameter and long lesions have to be treated.


One of the reasons for the length of the process is that even one of the most advanced solutions, combining the TURBO-Booster® and the TURBO Laser Elite catheters, may require a number of steps starting with atherectomy to create an initial pilot channel through the whole lesion, for example using the laser catheter alone, and only at later stages the laser catheter is loaded into the introducer sheath. The use of the catheter is based on several passages, each after rotation of the catheter. See Schwarzwalder U, Zeller T, Tech Vase Intery Radiol. 2010 March; 13(1):43-53.


Additional limitations of this solution include ineffective removal of arterial debris and high risk of artery walls injury, as mentioned, for example, in U.S. Pat. No. 6,962,585:

    • “An Excimer Laser Coronary Angioplasty system and procedure offered by Spectranetics of Colorado Springs, Colo., involves the insertion into an artery of a laser catheter containing a bundle of optical fibers and a stent with a guide wire. The laser catheter is advanced in the artery until the guide wire crosses a blockage, at which time bursts of ultraviolet (cool) laser light is transmitted through the fiber optic fibers to open a hole in the blockage. Thereafter, an x-ray contrast dye is injected into the blood stream to determine the extent to which the artery has been opened. This procedure does not remove substantial amounts of blockage because ultra violet radiation is too cool to melt the blockage. Rather, a hole is blasted through the blockage to accommodate the admission of a stent.
    • While the catherization system includes a filter, the filter is not sufficient to catch all debris which may flow downstream.
    • Such prior systems have failed because they have not effectively removed arterial blockage from the artery walls, and have not effectively removed arterial debris from the artery once the arterial blockage has been dislodged. In addition, such prior systems have not adequately protected the artery walls from physical or thermal injury. Further, many of the prior art devices embody numerous parts which tend to fail or shatter in a high temperature/high vacuum environment.” (id, p. 1, ln. 19)


An alternative approach using IR laser for thermal heating of a tip used to cut the plaques to be removed with suction is disclosed in U.S. Pat. No. 6,962,585. This approach may suffer from the limitations and risk involved with plaque removal based on non-selective heating. The approach proposed in this case is to use arterial guards in the outer part of the catheter that may limit the passage of the catheter and avoid getting closer to the walls. Other attempts to use thermal effects include a hybrid thermal probe, wherein most of the laser energy (Argon or Nd:YAG) is used to heat the hot tip in the catheter, and part of it escapes as laser light. Clinical results were not satisfactory to enable routine clinical use.


Additional prior approaches include use of a laser to core the plaque and use of mechanical means to “ingest” and remove the plaque. See, for example, U.S. Pat. No. 4,979,939. In Canadian Patent No. 1,326,800 a fiber is introduced to create an opening through which the distal rotary is introduced and the second fiber is used to vaporize the material collected by the blade. U.S. Patent Application Publication No. 2010/0125253 discloses a dual tip catheter for treating chronic total occlusions through which a fiber may be introduced.


In view of the complexity and limitations of the laser based technologies, the systems based on excimer laser have had limited spread in clinical use, and alternative mechanical methods for atherectomy have been developed, for example, wherein the plaques are “shaved” (the EV3 product), “drilled” (the Pathway product) or “sanded” with a rotating diamond coated brush (the CSI product). Each of these techniques may often suffer from inherent limitations such as procedure length, injury to the blood vessels, difficulty in dealing with calcified plaques in certain cases and, on the contrary, dealing with soft plaque (see Schwarzwalder U, Zeller T, Tech Vase Intery Radiol. 2010 March; 13(1):43-53) or discarding of plaque material into the blood stream


It should be noted that it is assumed by experts in the area that injury of healthy tissue and the characteristics of the tissue after plaque is removed may affect the healing (and initial hyperplasia) and the rate of restenosis which seems to be a limitation of some of the above-mentioned techniques. Furthermore, in view of the limited capabilities to remove plaque with many prior techniques, their current utility is limited mainly for use in conjunction with low pressure balloon angioplasty used after plaque is partially removed. The balloon then opens the vessel with the remaining plaque material.


The need to deal with complete or partial blockage in vessels applies also to artificial grafts, such as those implanted in the legs for bypass, for hemodialyisis access and more.


In-stent-restenosis. It is known in the art that in a significant percentage of the patients that underwent stent implantation, restenosis occurs within a few years after implantation. This is a major issue with bare-metal stents (BMS) and even introduction of drug eluting stents (DES) that show a robust decrease of restenosis still does not completely solve the problem.


Acute blockage of vessels. There is also a need for tools that quickly open blood vessels in patients that suffer from ischemic stroke (caused by blockage of a blood vessel) or in heart attacks with the minimal risk of perforation.


Removal of pacemaker and defibrillator leads. Presently there is a growing need to remove pacemaker and defibrillators leads in a subset of patients due to several reasons such lead fracture, abrasion of the insulation causing shorting and infections. Approximately 5 million leads are implanted worldwide and it is estimated that 4-7% will have to be removed at certain time point. It is estimated that over 100,000 leads were extracted in the US and Europe in 2010.


There are several approaches to remove transvenously introduced ICD leads. If leads have been in place for only a short period, they can frequently be removed by simple traction. After the leads are in place for long time scar tissue may withholds the leads during traction, the force applied to the leads is limited by the tensile strength of the insulation and conductor coils, therefore locking stylets and sheaths are used to enable a more forceful tension, but successful lead removal can still be very problematic when the leads is attached to sensitive tissue such myocardial wall. In severe cases lead extraction may require open surgery. The Spectranetics Excimer Laser and Cook Medical's Evolution products are currently used for lead removal using transcatheter techniques. The “debulking” of the lead using an excimer laser has yielded good clinical results but requires a large and expensive laser that does not allow wide use in any cardiology unit and a relative long learning curve is required.


There is a need for an effective and safe solution for removal of pacemakers and defibrillator leads in patients.


Management of Barrette's Esophagus. Barrett's Esophagus (BE) is a common disorder that is a major risk factor for esophagus cancer. The prevalence of the disorder is estimated to be in the range of 1-2%. See Ronkainen J, Aro P, Storskrubb T, et al. (December 2005) “Prevalence of Barrett's esophagus in the general population: an endoscopic study”, Gastroenterology 129 (6): 1825-31. The range of severity can vary from early stage to different grades of dysplasia to cancer. Prior attempts to manage this condition with Argon coagulation yielded controversial results. Alternative methods are based on RF ablation (RFA) (Halo® System), photodynamic therapy (PDT), cryo, thermal therapy or surgery as endoscopic mucosal resection (EMR). No method resulted in wide clinical acceptance that can enable routine use in a broad population instead of “waiting and watching” in early stages in the disease and specific therapies including esophagus resection in more sever conditions.


Furthermore, as no single technique has been established as the preferred method, a combination of techniques is used in certain cases. For example, there may be a consensus that RFA is useful for patients with BE and high-grade dysplasia (HGD), BE and intramucosal carcinoma as an adjunct to endoscopic mucosal resection (EMR). The use of RFA for BE with low-grade dysplasia (LGD) or intestinal metaplasia is not clearly established, see David E. Fleischer_Virender K. Sharma, Interventional and Therapeutic Gastrointestinal Endoscopy. Front Gastrointest Res. Basel, Karger, 2010, vol 27, pp 140-146. On the other hand, EMR sometimes does not allow removing all of the Barrett's lining but can be successful in removing a small cancer or a localized area of high-grade dysplasia. Because it does not remove all of the Barrett's lining, the Barrett's lining left behind can develop other areas of high-grade dysplasia or cancer. Therefore, EMR is sometimes combined with photodynamic therapy in an attempt to remove remaining Barrett's tissue or with RF ablation. Conversely, several photodynamic therapy studies have also reported that a few patients have a situation in which the Barrett's lining does not completely go away but is still there, underneath the new normal-appearing squamous lining (and detected when biopsy is performed that shows that small areas of Barrett's lining are still there underneath the new squamous lining.) In such a case, another course of treatment with another technique might be beneficial.


Complications of the current available techniques include perforations (making a hole in the esophagus), bleeding, strictures, light sensitivity in PDT and even death.


Removal of challenging lesions in intestine and stomach. Some of the polyps and adenomas (benign tumors) detected with an increasing percent in colonoscopy, with different imaging techniques, do not have a conventional “pedunculated” shape. Polyps that are not attached to the surface by a narrow elongated stalk are called sessile. Other polyps are not significantly elevated from the adjacent mucosa are called flat. Accordingly, the removal of large sessile and flat colorectal is more difficult than removal of pedunculated polyps and in many cases require using special endoscopy techniques to avoid perforation.


These lesions may be associated with high clinical risk. The incidence of cancer with submucosal invasion appears to be higher in flat-type lateral spreading tumors.


Endoscopic Mucosal Resection (EMR) is becoming the standard technique for resection of large sessile and flat colorectal lesions. For the more challenging lesions, Endoscopic Submucosal Dissection (ESD) can be used. ESD can be performed using a viscous injection solution for sustained submucosal lifting, a diathermy knife, and a plastic hood to help retract the polyp as it is dissected away from the muscularis propria.


Although these techniques are feasible anywhere in the colon, currently these techniques are technically challenging and time consuming and ESD carries a relatively high rate of major complication. Laser ablation is usually not perceived as an adequate solution for this application, as there is a need to assure adequate (i.e. complete) removal of pathological tissue and preferably to collect resected samples for histological analysis


There is thus an unmet need in the art for devices, systems and methods that would allow efficient and effective vascular interventions as well as removal of challenging lesions in the gastroenterology (GI) track (mainly in colon and stomach) and Barrett's esophagus management.


Removal of challenging lesions in gynecology and urology. There is a need for effective and safe tools for removal of pathological tissue in gynecology (cervical uterus) and urology (urinary bladder, prostate), wherein the depth of resection can be controlled while risk of perforation and bleeding is minimized.


SUMMARY OF THE INVENTION

There is provided, in accordance with some embodiments, a catheter for debulking of an undesired deposit from an inner surface of at least one of a blood vessel wall and a stent located in a blood vessel, the catheter having a tip section comprising: circumferentially-directed laser optics; and a circular-action cutter, wherein said circumferentially-directed laser optics is configured to transmit laser radiation for modifying an area of the undesired deposit thereby preparing said area for penetration of said cutter, wherein said cutter is configured to cut through said modified area and thereby debulk at least a part of the undesired deposit.


There is further provided, in accordance with some embodiments, a method for debulking of undesired deposit from an inner surface of at least one of a blood vessel wall and a stent located in a blood vessel, the method comprising, using a catheter: irradiating an area of the undesired deposit using a circumferentially-directed laser optics, thereby modifying said area; and cutting through said modified area using a circular-action cutter, thereby debulking at least a part of said undesired deposit.


There is further provided, in accordance with some embodiments, a catheter for debulking of an undesired deposit from an inner surface of at least one of a blood vessel wall and a stent located in a blood vessel, the catheter having a tip section comprising: a first wall having a circular cross section and having a sharp distal edge; and a plurality of optical fibers located along the surface of said first wall, wherein said plurality of optical fibers are configured to transmit laser radiation configured to modify the undesired deposit and thereby preparing the undesired deposit for penetration of said sharp distal edge of said first wall, wherein said first wall is configured to cut through said modified undesired deposit and thereby debulk at least a part of the undesired deposit.


There is further provided, in accordance with some embodiments, a method for debulking of undesired deposit from an inner surface of at least one of a blood vessel wall and a stent located in a blood vessel, the method comprising, using a catheter: using a catheter having a plurality of optical fibers, transmitting laser radiation towards an undesired deposit thereby modifying the undesired deposit and preparing the undesired deposit for penetration of a sharp distal edge of a catheter's wall; and advancing the catheter and cutting through the modified undesired deposit thereby debulking at least a part of said undesired deposit.


There is further provided, in accordance with some embodiments, a catheter for pacemaker and ICD (Implantable Cardioverter Defibrillator) lead extraction, the catheter having a tip section comprising: a first wall having a circular cross section and having a sharp distal edge; and a plurality of optical fibers located along the surface of said first wall, wherein said plurality of optical fibers are configured to transmit laser radiation configured to modify the tissue surrounding the lead thereby preparing the tissue for penetration of said sharp distal edge of said first wall, wherein said first wall is configured to cut through said modified tissue and thereby detach the lead from the tissue.


There is further provided, in accordance with some embodiments, a method for pacemaker and ICD (Implantable Cardioverter Defibrillator) lead extraction, the method comprising: using a catheter having a plurality of optical fibers, transmitting laser radiation towards a tissue surrounding the lead thereby modifying the tissue and preparing the tissue for penetration of a sharp distal edge of a catheter's wall; and advancing the catheter over the lead by cutting through the modified tissue surrounding the lead and thereby detach the lead from the tissue.


There is further provided, in accordance with some embodiments, a catheter for pacemaker and ICD (Implantable Cardioverter Defibrillator) lead extraction, the catheter having a tip section comprising: circumferentially-directed laser optics; and a circular-action cutter, wherein said circumferentially-directed laser optics is configured to transmit laser radiation for modifying the tissue surrounding the lead thereby preparing said tissue for penetration of said cutter, wherein said cutter is configured to cut through said modified tissue and thereby detach the lead from the tissue.


There is further provided, in accordance with some embodiments, a device for detaching undesired tissue from an inner wall of a body cavity, the device having a tip section in a shape of a cylinder's sector, the tip section comprising: a plurality of optical fibers located along an inner surface of the tip section and configured to transmit laser radiation to the undesired tissue; and a cutter having a shape of a cylinder's sector located inwardly and/or outwardly to the plurality of optical fibers, wherein said cutter is configured to cut through the undesired tissue and thereby detach at least a part of the undesired tissue from the inner wall of the body cavity.


There is further provided, in accordance with some embodiments, a method for detaching undesired tissue from an inner wall of a body cavity, the method comprising: using a plurality of optical fibers, transmitting laser radiation to an area of said undesired tissue, thereby modifying said area; and cutting through said modified area using a cutter, thereby detaching at least a part of said undesired tissue.


In some embodiments, an angle between said device and said endoscope's longitudinal axis is adjustable according to a required depth of peeling of said undesired tissue.


In some embodiments, cutting comprises rotatably cutting using a blade rotatable along an inner surface of a cylindrical tip section of the catheter.


In some embodiments, cutting comprises rotatably cutting using an annular blade.


In some embodiments, cutting further comprising vibrating said cutter.


In some embodiments, detaching the undesired tissue comprises peeling of the undesired tissue.


In some embodiments, mechanically weakening comprises ablation of said tissue.


In some embodiments, modifying said area of said undesired deposit comprises mechanically weakening said area.


In some embodiments, modifying said tissue comprises mechanically weakening said area.


In some embodiments, modifying said undesired deposit comprises mechanically weakening said area.


In some embodiments, said circumferentially-directed laser optics comprises a plurality of optical fibers located along an inner surface of the cylindrical tip section.


In some embodiments, said circumferentially-directed laser optics and said circular-action cutter are configured to operate simultaneously.


In some embodiments, said circumferentially-directed laser optics and said circular-action cutter are configured to operate intermittently.


In some embodiments, said cutter comprises a blade rotatable along said inner surface of said cylindrical tip section, inwardly or outwardly to said plurality of optical fibers.


In some embodiments, said cutter comprises an annular blade located along an inner or an outer surface of the cylindrical tip section, inwardly or outwardly to said plurality of optical fibers.


In some embodiments, said cutter is configured to have two positions, in a first position, the cutter extends further from a distal end of the tip section, and in a second position the cutter is retracted towards a proximal part of the tip section.


In some embodiments, said cutter is configured to shift from the first position to the second position when a force above a predetermined value is applied on said cutter.


In some embodiments, said cutter is configured to shift from the first position to the second position upon indication of a force applied on said cutter being above a predetermined value.


In some embodiments, said cutter is configured to shift from the first position to the second position when a force above a predetermined value is applied on said cutter.


In some embodiments, said cutter is configured to vibrate.


In some embodiments, said cutter is said catheter's wall, wherein said wall has sharp distal edges.


In some embodiments, said drug comprises: Elutax®, SeQuent®, Cotavance™ with Paccocath® coating technology, TADD (from Caliber Therapeutics, Inc.), Advance® 18PTX®, DIOR®, IN.PACT™ Amphirion, Coroxane or any combination thereof.


In some embodiments, said laser is a diode pump Holmium Fiber laser.


In some embodiments, said laser is a pulse laser with emitting radiation in the range of 2.8-3 microns.


In some embodiments, said laser is a pulse Thulium laser


In some embodiments, said laser is a pulse Thulium fiber laser.


In some embodiments, said laser is a Er:YAG laser


In some embodiments, said laser is a fiber laser configured to emit at 2.8-3 microns.


In some embodiments, said laser is a pulsed laser.


In some embodiments, said laser is a solid state triple Nd:YAG laser.


In some embodiments, said laser radiation is pulsed radiation.


In some embodiments, said one or more lead retraction elements are configured to grab the lead only when the catheter is moving outside of the body.


In some embodiments, said one or more lead retraction elements comprise a balloon.


In some embodiments, said plurality of optical fibers and said cutter are configured to operate simultaneously.


In some embodiments, said plurality of optical fibers and said cutter are configured to operate intermittently.


In some embodiments, said plurality of optical fibers are configured to modify an area of the undesired tissue thereby preparing said area for penetration of said cutter, wherein said cutter is configured to cut through said modified area and thereby detach at least a part of the undesired tissue.


In some embodiments, said plurality of optical fibers are located along an inner surface of said first wall.


In some embodiments, said plurality of optical fibers are located along an outer surface of said first wall.


In some embodiments, said plurality of optical fibers comprise one or more optical fibers having a proximal diameter larger than their distal diameter.


In some embodiments, said second wall comprises a sharp distal edge.


In some embodiments, said tip section is cylindrical.


In some embodiments, said tip section is expandable.


In some embodiments, the catheter further comprises a drug eluting balloon.


In some embodiments, the catheter further comprises a light concentrator at a distal end of said tip section.


In some embodiments, the catheter further comprises a second wall, wherein said plurality of optical fibers are located between said first and said second walls.


In some embodiments, the catheter further comprises one or more imaging elements configured to provide information on an inner part of said blood vessel.


In some embodiments, the catheter further comprises one or more imaging elements for monitoring the procedure.


In some embodiments, the catheter further comprises one or more imaging elements configured to provide information on an inner part of said blood vessel.


In some embodiments, the catheter further comprises one or more lead retraction elements.


In some embodiments, the catheter further comprises one or more openings for administering a drug.


In some embodiments, the circumferentially-directed laser optics comprises a plurality of optical fibers located along an inner surface of a cylindrical tip section of the catheter. In some embodiments, the device further comprises a light concentrator at a distal end of said tip section.


In some embodiments, the device further comprises one or more imaging elements configured to provide information on an inner part of said cavity.


In some embodiments, the device further comprises one or more openings for administering a drug.


In some embodiments, the device further comprises openings or tubing for flushing a cleaning solution.


In some embodiments, the device is configured for use in the gastrointestinal tract, urology or gynecology.


In some embodiments, the device is configured to mount on a tip section of an endoscope.


In some embodiments, the method further comprises administering a drug for preventing or treating restenosis.


In some embodiments, the method further comprises flushing a cleaning solution.


In some embodiments, the method further comprises imaging the inner part of said cavity.


In some embodiments, the method further comprises imaging the procedure.


In some embodiments, the method is used in endoluminal procedures m the gastrointestinal tract, urology or gynecology.


In some embodiments, the undesired tissue comprises a flat lesion and wherein the gastrointestinal tract cavity comprises an inner wall of the stomach.


In some embodiments, the undesired tissue comprises a flat lesion and wherein the gastrointestinal tract cavity comprises an inner wall surface of the stomach.


In some embodiments, the undesired tissue comprises a sessile polyp, flat polyps and NP-CRN (Nonpolypoid colorectal neoplasms) and wherein the gastrointestinal tract cavity comprises an inner wall surface of the colon.


In some embodiments, the undesired tissue comprises Barrett's tissue and wherein the gastrointestinal tract cavity comprises the esophagus, wherein said tip section is configured to match the typical anatomy of the esophagus.


In some embodiments, the undesired tissue comprises Barrett's tissue and wherein the gastrointestinal tract cavity comprises the esophagus.


In some embodiments, transmitting laser radiation and cutting are conducted simultaneously.


In some embodiments, transmitting laser radiation and cutting are conducted intermittently.





BRIEF DESCRIPTION OF THE FIGURES

Exemplary embodiments are illustrated in referenced figures. Dimensions of components and features shown in the figures are generally chosen for convenience and clarity of presentation and are not necessarily shown to scale. The figures are listed below.



FIG. 1A shows an exemplary cylindrical tip section of a hybrid catheter in perspective view;



FIG. 1B shows an exemplary cylindrical tip section of a hybrid catheter in a front view;



FIG. 1C shows an exemplary cylindrical tip section of a hybrid catheter inside a vessel with partial plaque blockage in a cross-sectional view;



FIG. 2 shows an exemplary tip section of a hybrid catheter, with one or more alterations with respect to FIGS. 1A-1C.



FIG. 3A shows a tip section which includes a hollow reflective light concentrator;



FIG. 3B shows a tip section which includes a solid-state light concentrating waveguide;



FIGS. 3C-3E show the usage of tapered fibers;



FIGS. 4A-4B show a circular-action cutter;



FIG. 5 shows a cross-sectional view of an expandable tip section;



FIGS. 6A-6B illustrate a tube 600 introduced through the catheter and ending with an array of nozzles or apertures;



FIGS. 7A-7B illustrate the use of a roller 700 to stain the tissue;



FIGS. 8A-8B illustrate apertures 800 built into the catheter's housing;



FIGS. 9A-9B illustrate an array of tubes or needles 900a-b which are used to administer the drug;



FIG. 10 shows an exemplary tip section of a hybrid device mounted on an endoscope;



FIG. 11 shows a hybrid catheter mounted on an endoscope, during a procedure of detaching undesired tissue;



FIG. 12 shows a catheter assembled on a commercially-available endoscope; and



FIGS. 13A-13C show a cross section of a hybrid catheter over a lead to be extracted.





DETAILED DESCRIPTION

An aspect of some embodiments relates to a hybrid catheter and methods for using the same in endoluminal interventions. For example, present embodiments may be useful in various vascular applications, such as atherectomy, angioplasty, debulking of plaque in in-stent restenosis, leads extraction, thrombectomy in chronic peripheral and coronary artery diseases and for management of acute blockage of vessels in coronary and neurovascular applications. Another example is the use of embodiments in gastroenterology, such as for removal of sessile and flat lesions in the GI track, Barrett's Esophagus management and in analogous applications requiring removal of tissue from the inner walls in gynecology and urology interventions.


The hybrid catheter may be based on a combination of laser and mechanical removal (also “debulking”) of an undesired material from a bodily lumen. In vascular interventions, the catheter may be configured to weaken and/or even cut and detach undesired material with a laser and then, even in cases where the plaque material was not entirely removed, detaching the rest of the plaque material by mechanical means, such as using a blade. The laser may change the mechanical characteristics of tissue, and thereby improve performance of mechanical tools such as various types of blades or shavers. By way of example, the laser may make a soft tissue crispier so it can be effectively crushed using the mechanical tool.


Advantageously, usage of the present catheter may obviate the need to photo-ablate (evaporate) most or all of the undesired material. Accordingly, the process may be faster and result in lesser by-products than in common laser ablation, lesser associated mechanical stress and lesser other side effects such as thermal injury resulting from photo ablation. The process may allow using smaller lasers wherein energy is focused at a smaller area and wherein mechanical tools remove traces remaining in the treated area and facilitate further penetration of the laser beam to proceed in effective ablation. In addition, challenging calcified tissue may be successfully treated, despite the difficulty in many of today's common mechanical or excimer lasers to delicately detach such tissue from the vessel's walls. The present catheter, advantageously, provides for controlled cutting of plaque with minimal or no damage to the vessel's walls.


This hybrid catheter disclosed herein may be used (for example in atherectomy) alone and/or in conjunction with low pressure balloon angioplasty, stenting, for treating in-stent restenosis with no damage to the stent, and/or for treatment of acute blockages due to plaques and or thrombus (thrombectomy).


The terms “cut”, “dissect”, “resect”, “detach”, “debulk” and “remove” may be used here interchangeably.


According to some embodiments, the catheter comprises a tip section, which may be essentially in a cylindrical shape, having circumferentially-directed laser optics, optionally in the form of one or more optical fibers, configured to deliver laser radiation, and a circular-action cutter including one or more blades configured to assist in cutting and/or detaching undesired materials (also “deposits”) from an inner surface of a blood vessel. The one or more optical fibers may be circumferentially-directed, namely, they may be located along an inner surface of the cylindrical tip section, which is near the periphery of the tip section. Alternatively, the circumferentially-directed optical fibers may be located elsewhere but directed, by way of orientation and/or optical focusing, to radiate an area in front of the circumference of the tip section.


The circular-action cutter may be located in a central part of the tip section, for example, surrounded by the optical fibers. Alternatively, the circular-action cutter may be located in the periphery of the tip section and the one or more optical fibers are located in a central part of the tip section, for example, surrounded by blades.


According to some embodiments, the one or more optical fibers and the one or more blades are located in the periphery of the tip section.


According to some embodiments, the one or more optical fibers and the one or more blades are located in a central part of the tip section.


According to some embodiments, the circular-action cutter lays on a spring so that a maximum force applied by the cutter is predetermined in order to avoid potential damage, yet be effective. The tip section may include an inner channel maintained at a relative low pressure to suck the undesired material which may be plaque, thrombus material, debris, saline solution used for cleaning and/or the like.


Optionally, a motor is provided to rotate the circular-action cutter in order to improve fragment cutting and/or detaching. Additionally or alternatively, the motor or a different motor may be used to rapidly vibrate the circular-action cutter in order to improve fragment cutting and/or detaching.


Optionally, the circular-action cutter is heated to improve its performance. This may be done by an external heat source, electrical means and/or by the laser radiation.


According to some embodiments, the catheter tip may be expandable, such that its diameter may be increased after its introduction into the vessel.


According to some embodiments, the catheter tip may include means for deflection, such that effective working area will be larger than the catheter diameter and enable off-axis work.


According to some embodiments, the catheter may be useful in cases of Chronic Total Occlusions (CTO), where a guidewire cannot normally be used to pass lesions totally blocking the vessel, and therefore atherectomy is often not feasible, since usage of a guidewire often dictates a certain relative position, and angle in particular, of the catheter's tip section versus the vessel.


An example of an appropriate laser of some embodiments is a solid state ultraviolet (UV) laser emitting pulses in approximately 355 nm and/or 266 nm. An example of an appropriate laser is the Qauntel CFR400, emitting 50 mJ, 10 ns pulses of 355 nm at 50 Hz and/or 40 mJ of 266 nm at 40 Hz. Another example is an Excimer laser.


In case of using significantly high repetition rates, thermal effects in the tissue may become a problem This can be at least partially resolved by minimizing ablation area (depth and width), use of short laser pulses and with saline flushing. Another option includes sequential illumination of fibers in a manner that not all the fibers are exposed to laser ration simultaneously, in order to enable thermal relaxation of the affected tissue.


In an embodiment, dyes or substrates may be used to enhance absorption at certain wavelengths, such as 355 nm. For example, sensitization with haematoporphrin or tetracycline prior to the procedure, in order to enhance ablation of the pretreated atheromatous plaque but not insensitised or normal arterial wall.


Another example of a laser of some embodiments is a laser emitting pulsed radiation in the mid-infrared (IR) region, such as in the range of 2.8-3 micrometers, a range where water is very effectively absorbed. Additionally or alternatively, radiation at around 2 microns may be used, with a preference for thulium laser emitting at 1910-1940 nm range wherein there is higher absorption of water preferably combined with Q-switched modulation wherein ablation is more effective and reduces lateral damage. For 3 micron emission, an Er:YAG may be used, or another source such as a Mid-IR Holmium Fiber Laser Directly Pumped with Diode Laser that emits at 2840 nm using fluoride fibers [see Optics Letters, Sep. 1, 2007, pp. 2496-2498].


Yet another example is usage of a third harmonic of a Nd:YAG laser at 355 nm, preferably a compact, all solid state, diode pumped laser. The 355 nm radiation usually has a deeper penetration capability compared to the 308 nm radiation, in the depth range of 100 micron or more in relevant tissues and materials. Optionally, very short pulse widths (such as <1O ns) are used, in order to obtain a higher power density, and, in particular, to be able to ablate calcified plaques. In accordance with some embodiments, the energy per pulse is in the range of 10-1O0 mJ and the pulse frequency is in the range of 10-1O0 Hz. Optionally, the area of ablation may be flushed with a saline solution in order to reduce side effects (such as cavitation), clean the area of ablation and catheter and/or facilitate collection of debris.


One of the advantages of using 355 nm radiation is that is considered relatively nonmutagenic. The 308 nm radiation of the xenon chloride laser is in the UVB range, which is known to have mutagenic risks. [Walter Alexander. Journal of Clinical Laser Medicine & Surgery. AUGUST 1991, 9(4): 238-241. doi:10.1089/clm.1991.9.238.]


Some prior studies have indicated that third harmonic lasers are generally less suitable to endovascular interventions than 308 nm lasers, due to longer penetration rates and reduced effectiveness of ablation (see, for example, Grundfest W S et al., Am J Surg. 1985 August; 150(2):220-6; and Frank Laidback et al., Lasers in Surgery and Medicine 8:60-65 (1988)). The present embodiments, however, may successfully utilize third harmonic Nd:YAG lasers instead of complex and expensive Excimer lasers. The present embodiments address several problems. For example, in some embodiments, it may not be necessary to laser-ablate all the material whose removal is desired, but rather the laser and the mechanical cutter may share the task; the laser may ablate and/or weaken at least some of the material, while the mechanical cutter completes the job by finally detaching the material from the walls.


In some embodiments, a laser that emits radiation in 266 nm may be used. This wavelength has a shorter penetration rate in addition use of compact Excimer laser emitting radiation at 308 nm, as currently used, can be utilized with the current embodiments. According to some embodiments, a system may include means that enable an operator to switch between 266 nm and 355 nm, generated from the same Nd:YAG laser, and means to control power, repetition rate and/or exposure/illumination of specific fiber groups.


An alternative embodiment of the present invention replaces UV lasers with a laser with radiation in the 2 micron or 2.8-3 microns, in which ablation is very effective.


Holmium lasers are conventionally used for 2 microns but Thulium lasers have a stronger water absorption and smaller absorption length, which makes them especially suitable for some embodiments. For example, in an embodiment, pulsed fiber thulium laser is used. Alternatively, a solid state laser may be used in order to increase pulse power per pulse, which is currently limited in fiber lasers and in view of the limited pulse rate that can be used in order to minimize heat accumulation and damage.


Laser in 2.8-3 micrometer may be Er:YAG. Er:YAG Q-switched are available with pulses in the hundreds of nanosecond range, which may be suitable for present embodiments. See, for example, M. Skorczakowski, et al, Laser Physics Letters Volume 7, Issue 7, pages 498-504, July 2010. Another laser example which may be suitable for specific embodiments is Pantec's model DPM-15 solid state laser, emitting microsecond pulses in the mJ range at hundred of KHz.


In an embodiment, fiber lasers which may be directly diode-pumped, such as a Mid-IR Holmium Fiber Laser, are used. This laser may be pumped from ground level (518) to an excited energy band (516) with radiation at about 1150 nm, and the relaxation bands may lead to emission at 2840 nm (relaxation to band 517) and 2100 nm in relaxation to ground state. Accordingly, this laser may be directly pumped with recently developed high-power, high-brightness diode lasers based on highly strained InGaAs quantum wells that produce output at 1148 nm. See Optics Letters, Sep. 1, 2007, pp. 2496-2498 and Stuart D. Jackson Optics Letters, Vol. 34, Issue 15, pp. 2327-2329 (2009).


The laser may be selected according to the selected resonator optics, for example fluoride fiber lasers to emit laser radiation on the 2.9-μm transition (516 to 517) and silica fiber lasers to emit radiation on the 2.1-μm transitions (517 to 518). An advantage of an embodiment using a laser in the region of 2.9-3 micron is that the absorption is very high and results in very short length of absorption, in the order of 15 microns only. Therefore, the relaxation time is shorter so the pulse rate may be increased to above 100 Hz in order to accelerate the procedure.


In addition to the laser beam that interacts with the undesired material, a laser with controlled pulse rate and/or power may be used to interact with the liquid between the fiber tip (exit of laser beam) and tissue, either to allow for “opening” of a passage for the beam (e.g., a channel wherein light is not absorbed when UV radiation is used) to the tissue prior and adjunctive to the required interaction with the tissue, and/or to facilitate the process (when mid-IR radiation is used) benefiting from the “water spray” effect. By way of clarification the tip can be in mechanical contact with the tissue being ablated or not.


Reference is now made to FIGS. 1A, 1B and 1C, which show an exemplary cylindrical tip section 100 of a hybrid catheter in perspective, front and cross-section views, respectively, in accordance with an exemplary embodiment. The remainder of the catheter's shaft (not shown) may, in some embodiments, be biocompatible polymer tubing, optionally coated, to minimize friction with the vessel's walls.


Tip section 100 is positioned at the distal end of the hybrid catheter, the end which is inserted into the blood vessel. Tip section 100 may include a housing 102, for example a cylindrical one, at least one optic fiber(s) 104 positioned along an inner surface of housing 102, and a circular-action cutter (or simply “cutter”) 106 positioned inwardly of the optic fibers. Alternatively, in an embodiment (not shown), the circular-action cutter may be positioned outwardly of the optic fibers. It is intended that the following description of the embodiments in which the circular-action cutter is positioned inwardly, be applied, mutatis mutandis, to the alternative, not-shown embodiment. Optionally, optic fiber(s) 104 are delimited and/or supported by a first inner wall 108. Further optionally, cutter 106 is delimited and/or supported by a second inner wall 110.


In accordance with some embodiments, the catheter is used with a standard guidewire.


In accordance with some embodiments, the catheter is connected to a suction pump that generates low pressure to collect undesired material, saline and/or the like through the catheter. The pump may be a peristaltic pump, which mounts externally to the fluid path, to avoid any contamination of the pump. Optionally, this obviates the need to use disposable parts.


Optic fibers 104, serving as the laser optics of the present hybrid catheter, may be connected, at their proximal end (not shown) to a laser source characterized by one or more of the parameters laid out above. Optic fibers 104 may deliver the laser beams from the source towards the intervention site in the body. In tip section 100 of FIG. 1C, optic fibers 104 are shown as they emit laser towards undesired material 114. One or more areas 116 in undesired material 114 may consequently be modified or even ablated by the laser. Then, cutter 106 may more readily cut into undesired material 114 and detach at least a part of it from the vessel's walls 118.


Cutter 106 is optionally an annular blade extending to a certain depth inside tip section 100 and coupled to a suitable motor (not shown), located in the tip section or further in the shaft, supplying rotary and/or vibratory power to the blade. Optionally, one or more flexible members, such as a spring 112, may interact with cutter 106 at its base, to allow it to retract and protrude from housing 102. Tip section 100 of FIGS. 1A-1C is shown with cutter 106 in its protruding position, while tip section 100b of FIG. 1C is shown with the cutter, now marked 106b, in its retracted position. The length of protrusion out of housing 102 may be, for example, up to about 350 microns when treating blood vessels. When protruding, cutter 106 is used for detaching undesired material (also “deposit”) 114 from an inner surface 118 of a blood vessel 120. According to some embodiments, when a certain force (for example, above a predetermined value) is applied to cutter 106 from the front, which may be a result of blockage in blood vessel 120, the cutter may shift its position and retract into housing 102.


The annular blade of cutter 106 may have sufficiently thin edges, such as around 100 microns. Suitable blades may be tailor-made by companies such as MDC Doctor Blades, Crescent and UKAM. The blade may optionally be mounted at the end of a rotatable tube rotated. Such tubes are available from manufacturers such as Pilling, offering a line of laser instrumentation and blade manufacture. The blade may be metal or manufactured by molding a material such as plastic which is optionally coated with a coating having proper characteristics for in-vivo use.


An exemplary tip section may have an external diameter of approximately 5 mm, an internal diameter (within the innermost layer, be it the cutter or an extra wall) of approximately 3.4 mm, and optical fibers each having an approximately 0.1-0.2 mm diameter.


Reference is now made to FIG. 2, which shows an exemplary tip section 200 of a hybrid catheter, which may be similar to tip section 100 of FIG. 1 with one or more alterations: First, one or more fibers 222 of the optical fibers existing in tip section 200 may be used for imaging the lumen of a blood vessel 220 by transporting reflected and scattered light from inside the lumen to an external viewing and/or analysis device (not shown) located externally to the body. This may aid in avoiding perforation of vessel 220 and allowing for on-line monitoring of the intervention process. Second, tip section 200 may be maneuverable, so as to allow different viewing angles and/or in order to align the laser beams and a cutter 206 differently. Third, a cleaning channel (not shown) may be present inside tip section 200 and extending outside the body, through which channel suction 224 is applied in order to evacuate debris of the undesired material which were treated by the lasers and/or cutter 206. These optional alternations are now discussed in greater detail:


A conventional manner for detection of plaque and other lesions and for monitoring of vessel treatment is based on ultrasound and fluoroscopy. Here, however, one or more fibers 222 may be utilized for detection of lesions and/or to monitor the intervention process on-line, based on the reflection and/or scattering of the laser light from the vessel and/or the deposits. Alternatively or additionally, a different source of illumination may be used, such as through one or more other fibers. The captured light may be transmitted to a sensor such as a CCD, a CMOS or a MOS. The sensing may include a filter or means for spectral imaging, to gain information about the material characteristics (plaque, tissue, calcified plaque, blood clot, etc.). This may enable a quick and effective procedure with minimal risk of perforation, and may enable debulking procedures wherein a guidewire cannot or should not be used.


The angle of tip section 200 may be controlled to enable by means of tip deflection material removal in a cross-section larger than the catheter size. This may be done by mechanical means, such as by selective inflation and deflation of at least two balloons (not shown) attached to the tip section externally at different angles, or a balloon with different compartments 226a-d. Another example is usage of links forming a joint 228, controllable from outside the body using one or more wires (not shown).


The laser optics of some embodiments will now be discussed in greater detail. The laser beam may be directed through fibers each having a core diameter optionally in the range of 40-250 microns. In a configuration where the catheter's circumference is, for example, 15 mm, using fibers with an outer diameter of 50 microns will result in using approximately 300 fibers with a cross-section area smaller than 1 mm2, so that for a coupling efficiency of 75%, the energy at the exit of each fiber will be close to 40 mj/mm when pumped with a 50 mJ laser. Adequate fibers for some embodiments may be all-silica fibers with a pure silica core. These fibers can usually withstand about 5 J/cm2 in the input. Some embodiments include fibers with a numerical aperture (NA) in the range of 0.12-0.22. An example of a relevant fiber is FiberTech Optica's SUV1O0/ll0AN fiber for UV application and the low OH version SIR100/140AN for use with laser in the 1900-2100 nm range or Infrared Fiber Systems, IR Photonics and A.RT. Photonics GmbH fibers for transmission of radiation in the 2900-3000 range. Embodiments of single mode or multimode may be realized while preservation of beam quality is important but not mandatory in certain embodiments. Some embodiments may include microlenses at the tip area to manipulate the beam at each individual fiber exit.


The power required for effective ablation with 355 nm, 10 nsec pulses (approximately 30-60 mJj/mm2) is close to the damage threshold of certain fibers or above it, which lead, in existing products, to the need of extended pulse length, for example. According to some embodiments, high peak power is maintained and accordingly the catheter may include means for delivery of the laser power through relatively bigger optical fibers, e.g. 100 or even 300 micron fibers that do not extend all the way to the end of the tip section, as schematically illustrated in FIGS. 3A-3E.



FIG. 3A shows a tip section 300 which includes a hollow reflective light concentrator 304a with a straight profile or a concave profile (as shown), used to concentrate light from at least two fibers (shown jointly at 304). Hollow concentrator 406a may have metal-based or dielectric coating. Hollow concentrator 304a may form a ring shape surrounding a cutter 306, in manner that radiation from all the fibers is delivered with one concentrator, so that a relatively uniform ring of pulsed radiation is generated at the exit. The exit may include a window (not shown in the figure). Optionally, the optical path may be maintained clean with flushing of saline. Flushing may be through an opening in the front or from the side, between the catheter and an extra lumen that can also facilitate catheter movement in the vessel or in certain embodiments through the central lumen.



FIG. 3B shows a tip section 330 which includes a solid-state light concentrating waveguide 334a for concentrating light from at least two fibers (shown jointly at 304). Solid-state waveguide 334a may be made, for example, of Silica with a reflective coating, or a combination of two materials such as Silica and Fluoride-doped Silica.


Solid-state waveguide 334a may be optically coated at the interface with the fiber(s), to improve optical throughput from the fiber(s) to the concentrator. Alternatively, the two may be welded.



FIGS. 3C-3E illustrate the usage of tapered fibers, such as those available from Oxford Electronics. The fibers may be thick 340 at the proximal end of the catheter's shaft, and thin 342 at its distal end—as seen in cross-section. FIG. 3E shows a single tapered fiber 340a in perspective view.


Reference is now made to FIG. 4A, which shows another option for a circular-action cutter, in accordance with an embodiment. The circular-action cutter here may be a rotating blade 406 which is rotatable, for example, using a flexible shaft 460 which centrally rotates a plate 462 peripherally connected to the rotating blade. Flexible shaft 460 may be capable of delivering a limited amount of torque, especially when there is bending in the artery, etc. Common mechanical atherectomy devices sometimes use very high rotation speeds to compensate for that. Present embodiments reduce the need for high moments, as the blade is active in an area which has been prepared, namely—cut or at least modified by the laser. Furthermore, the fact that lower torque and rotating forces are applied to the atheroma/plaques, decreases the radial forces applied to the vessels.


Reference is now made to FIG. 4B, which is mostly similar to FIG. 4A, except for the way rotating blade 406 is being rotated. Rotating blade 406 may be rotated by a miniature motor 464 and suitable transmission 466. Appropriate miniature motors are available from manufacturers such as Namiki, which developed a 1.5 mm-diameter micro-geared DC motor.


Optionally, rotating blade 406 of FIGS. 4A-4B may have shapes that facilitates collection and/or scraping of debulked material, to facilitate collection of debris.


In order to enable effective debulking in blood vessels, catheters of different dimensions may be used, for example in the range of 4-22 French (approximately 1.3-7 mm). The use of a larger catheter holds the advantage of enhancing the intervention process, but raises an issue of a large opening required for introduction into the vessel and/or accessibility within the vessel itself. Therefore, according to some embodiments, the diameter of the catheter, at least at its tip section, may be expandable. A first example is shown in FIG. 5, which is a cross-sectional view of an expandable tip section 500. A housing 502 of tip section 500 may be made of a relatively flexible material, compared to the rest the catheter's shaft. When the catheter reaches the debulking site, tip section 500 is expanded, to form an outwardly-tapered shape. This expansion may be achieved by introducing a mechanical element which applies pressure on one or more parts in tip section 500. Fibers 504 that transmit the laser beam, may then be inserted into the catheter's walls. Since when the tip section 500 is expended the distance between the fibers also extends, more fibers may be inserted into the walls. Optionally, the mechanical element introduced to expand tip section 500 includes cutter 506. Optionally, expandable tip section 500 may be used in conjunction with the tip section deflecting means of FIG. 2.


In another embodiment of a catheter with an expandable tip section, materials with shape memory, such as Nickel Titanium (known as Nitinol), may be used. The catheter, or at least its tip section, is compressed before introduction into the body, and naturally returns to its pre-compressed shape after it is introduced to the lumen. Nitinol may be used in a structure of a mesh or a braid, to provide sufficient radial force while enabling contraction with low enough radial forces when the catheter is retracted. Some flexibility may still remain at the tip section, to allow accommodation to the physiological shape of lumen. The tip may also include means for controlled deflection.


In some embodiments, the catheter may perform local delivery of drugs which reduce the incident of restenosis, such as Paclitaxel and its derivatives, or soluble forms such as Coroxane. The drug may remain in the site post-treatment and assist in lumen recovery, while preventing overdosing and systematic effects.


The drug administration following the removal of undesired material from the vessel or stent may be achieved by means such as: (i) spraying of drug from nozzles in the external surface of the catheter, or with a tube that includes an array of nozzles at its end, threaded through a suitable channel in the catheter; (ii) by a roller that “paints” the tissue; (iii) by a drug-coated balloon; (iv) by a balloon that includes means to deliver drug through channels in its wall; (v) brushes in the catheter walls; (vi) tubes with nozzles which may change their direction on the way in and out the material removal site.


To optimize long-term efficacy, some embodiments provide means for deep administration of the drug, to be sustained in the deeper layers of the arterial wall or even in remaining plaque but not in the endothelium, thereby allowing new endothelial cells to grow and re-align the lumen, to inhibit restenosis in deep cell layers after the lumen has been restored and re-endothelialized. This may be accomplished by means such as pressure-controlled drug administration, administration below the surface and/or selection of adequate drug forms.


In order to increase absorption of plaque material, the treatment procedure may include administration of one or more substances that increase absorption of plaque at 335 nm such as treating with tetracycline for which the uptake by plaque is a few times larger than in normal tissue. See, for example, Murphy-Chutorian D, et al, Am J Cardiol. 1985 May 1; 55(11):1293-7.


For blood vessel treatment, it is often desired to administer the drug in the deeper layers of the arterial wall but not in the endothelium, thereby allowing new endothelial cells to grow and re-line the lumen. As a result, the drug continues to inhibit restenosis in deep cell layers after the lumen has been restored and re-endothelialized, while, on the other hand, overdosing and systematic effects are eliminated. In some of the cases some plaque material remains on the vessel's walls or stent and the drug formulation and means of administration should take it in account.


Examples of applicable drugs include: Elutax®, SeQuent®, Cotavance™ with Paccocath® coating technology, TADD (from Caliber Therapeutics, Inc.), Advance® 18PTX®, DIOR®, IN.PACT™ Amphirion, Coroxane and more.


The conventional way to administer these drugs to avoid restenosis is with coated balloons. Alternative drug forms such as Coroxane may be administered via IV promptly after the procedure, but this would not result in local administration. It has been suggested in the literature to perform a two step process wherein a coated balloon follows atherectomy, but this would result in a more complex and costly procedure that can limit routine clinical use.



FIGS. 6A-6B, 7A-7B, 8A-8B and 9A-9B include schematical illustrations of a number of exemplary tip section embodiments suitable for local administration of drugs.



FIGS. 6A-6B illustrate a tube 600 introduced through the catheter and ending with an array of nozzles or apertures 602 that spray the drug on demand.



FIGS. 7A-7B illustrate the use of a roller 700 to stain the tissue. The catheter may include means to allow the roller to get at least partially inside a groove 702 before the debulking procedure, and exit the groove when needed to transfer the drug to the tissue. Roller 700 may include means to apply pressure to the walls in order to increase drug delivery and/or expand the stent in in-stent restenosis (ISR) applications.



FIGS. 8A-8B illustrate apertures 800 built into the catheter's housing, and configured to be opened only when needed.



FIGS. 9A-B illustrate an array of tubes or needles 900a-b which are used to administer the drug in a manner that will increase its sustainability. Means to allow the angle of the tubes relative to the catheter to change before and after the debulking procedure and/or in the way inside and outside from the lumen/stent are provided. The tubes may be facing forward 900a when moving forward and backwards 900b when moving backwards. The tubes are optionally made of a flexible, biocompatible material.


Further examples of drug administration may include: a brush to transfer the drug through nipples in the wall of the catheter; a balloon for administration of drug; a balloon surrounding the catheter and being coated with the drug and inflated after the debulking procedure; a balloon with nipples that are used to administer drug on demand; and a coated balloon inserted through the cleaning channel of the catheter.


The embodiments disclosed herein are brought as examples and can be combined for the purpose of vascular intervention in peripheral, coronary and neurovascular applications in chronic and acute conditions and in other medical applications wherein stents have to clean such as in gastro and urology and in applications wherein lumens have to be created or extended such as Benign Prostatic Hyperplasia.


Another clinical application, according to some embodiments of the present invention, is in removal of undesired tissue from a body cavity during an endoluminal procedure. Such procedures can be performed for example in gynecology, urology and in gastroenterology. Such procedures may include, for example, removal of flat and/or large lesions in the gastrointestinal (GI) track and in management of Barrett's esophagus. The motivation is to remove the undesired pathological tissue with minimal complications (e.g., in case of Barrett's esophagus, without esophageal perforations and strictures). This clinical application may require modified embodiments of the hybrid catheters disclosed herein in accordance with some embodiments. FIG. 10-FIG. 12 illustrate catheters for detaching undesired tissue from an inner wall of a body cavity, for example, but not limited to, Barrett's esophagus management, according to embodiments of the invention.


The first embodiment is a hybrid catheter which combines a utility of laser radiation to ablate and cut/detach the undesired pathological tissue or modify its mechanical characteristics and mechanical means such a blade or a sharp edge of a wall of the catheter to complete the detaching. This way, the tissue is resected/dissected using the laser radiation and the blade/wall's edge. Thus the blade/wall's edge does not need to be too sharp and are thus configured to cut the tissue without the risk of potential perforation or damage to the body cavity.


Reference is now made to FIG. 10, which shows an exemplary tip section 1000 of a hybrid device in perspective view, mounted on an endoscope 1500, in accordance with an exemplary embodiment. The remainder of the catheter namely—its shaft (not shown) may, in some embodiments, be biocompatible housing, optionally coated so as to reduce friction with the cavity's wall. Endoscope 1500 may be any commercially available scope having, inter alia, working channel 1502, for insertion of medical tools, water/air injector(s) 1504 for cleaning and insufflation, and illuminators 1506. Endoscope 1500 may also include a camera 1508 including CCD, CMOS or MOS sensors for example and optics.


Tip section 1000 is positioned at the distal end of the hybrid catheter, the end which is inserted into the body cavity such as the esophagus. Tip section 1000 has a shape of a sector of a cylinder and is generally configured to be mounted on top of an endoscope (for example, as used in upper endoscopy or colonoscopy). The shape of tip section 1000 is also configured match the typical anatomy of the body cavity to which it is intended to be inserted. Of course, the tip section of the hybrid catheter (device) may have other appropriate shapes and forms, and can mounted in certain embodiments on another working tool that is used to manipulate it while the process is monitored with another camera such as in laparoscopic procedures. Tip section 1000 may include two walls, an external wall 1002 and an internal wall 1004. One of the walls (external wall 1002 and an internal wall 1004) or both of them may have sharp distal edges to facilitate cutting through the undesired tissue. One of the walls (external wall 1002 and an internal wall 1004) or both of them may be coated with a material that provides sharper edges. At least one optic fiber(s), typically a plurality of optical fiber(s) 1006 are positioned between external wall 1002 and an internal wall 1004. Alternatively, in an embodiment (not shown), there may exist only one wall and the optic fibers may be located along an internal or an external surface thereof. Alternatively, in an embodiment (not shown), there may exist a cutter (similar to the cutter shown in FIGS. 1A-1C only having a shape of a sector of a cylinder). In another embodiment, external wall 1002, an internal wall 1004 and/or a cutter (blade) may have two positions, retracted position and protruded position (configured for cutting).


The external wall 1002, an internal wall 1004 and/or a cutter (blade) are configured (such as by virtue of sharpness) to cut through the undesired tissue and thereby detach at least a part of the undesired tissue from the inner wall of the body cavity. If a blade is present, it may be a rotary-action blade and/or a vibrating blade. According to some embodiments, optical fibers 1006 are configured to transmit laser radiation configured to modify an area of the undesired tissue thereby preparing said area for penetration of external wall 1002, an internal wall 1004 and/or a cutter (blade).


According to some embodiments, the blade may be mounted in a spring so that when force is applied beyond a certain predetermined level the blade enters into its compartment (shifts to retracted position). Alternatively, in another embodiment the position of the blade may be controlled by a physician. This way, the blade is not sharp enough to cut the tissue without the laser so as to avoid potential perforation. Flushing of saline or another appropriate solution at the edge of the catheter may be used to maintain an optical clean path, remove unnecessary material and reduce potential thermal damage and use a “water spray” effect with mid-IR radiation sources.


Reference is now made to FIG. 11, which shows a hybrid catheter mounted on an endoscope, during a procedure of detaching/resecting (“peeling”) an undesired tissue, according to some embodiments. Hybrid catheter 1001 includes a tip section 1000, transmitting laser radiation and cutting through the tissue. In this figure, hybrid catheter 1001 is used to remove the Barrett's tissue 1008. The illustration shows that different layers can be targeted and removed. Barrett's tissue 1008 (or any other undesired tissue) is cut by catheter and lifted. The catheter, such as catheter 1001, may be (not necessarily) assembled on a commercially available endoscope, such as endoscope 1600 (FIG. 12). According to some embodiments, the tip section of the hybrid catheter (particularly but not limited to) in interventions in the GI track may be position in predetermined angle versus the scope axis and thereby predetermining the depth of penetration of the tip according to the peeling depth required.


“Peeling” like mode can be thought of in analogy to a “carpenter plane” but using a “hybrid blade”. The depth of peeling can be adjusted according to the clinical condition such as the depth for Barrett's removal or required according to the stage of the disease and similarly in flat lesion in other places of the GI track. Accordingly the position of the blade knife can be adjusted as well as the distance between the blade and the plane. The catheter with a hybrid blade can be located at a predetermined angle/position and distance from the plane of the endoscope or another tool used to hold the tip. In this embodiment that catheter can be used to make the initial incision of the tissue as a few laser pulses are used to enable generation of a cut to allow the blade to cut through the required layers and then followed by movement of the catheter with the help of the scope over the organ in forward or backwards direction according to the position angle of the catheter.


In accordance with some embodiments the catheter is inserted through the working channel of a standard endoscope or through a special opening made in a dedicated scope. Some embodiments include using a tip with a memory shape that is contracted for introduction through the working channel and is expanded when it exits the endoscope tip. Such a catheter may be based on use of Nitinol. These embodiments enable the physician to perform a diagnostic procedure and, if a pathology 1s found, to introduce the resection catheter.


In another embodiment depending on the pathology the laser wavelength can be selected to enable reduced tissue penetration or surface ablation such as in 355 nm or 2.8-3 microns lasers or deeper with the 266 nm laser. For below the surface tissue interaction an embodiment of the invention includes a use of a mid-IR laser which had a longer penetration depth. A Thulium laser (potentially a Thulium fiber laser@ lambda=1908-1940 nm, wherein wavelength is matched according to the embodiment to compensate for water absorption wavelength change depending on temperature) may be used for this application since it has a better matching with water absorption length around 2 microns compared to Holmium:YAG and accordingly penetration depth is limited to a few hundred microns and also pulse rate can be increased comparing to Holmium without thermal damage.


One of the potential advantages in using the “hybrid catheter” for debulking of required tissue from lumens such as in the GI track is the side effect of the laser and this is enhancing homeostasis and avoid bleeding. Depending on the specific laser used the effect may not be sufficient to avoid bleeding and some embodiments may include use of an additional laser for the purpose of hemostasis preferably delivered through the same optical fibers.


In accordance with some embodiments, the catheter is connected to a suction pump that generates low pressure to collect undesired material, saline and/or the like through the catheter. The pump may be a peristaltic pump, which mounts externally to the fluid path, to avoid any contamination of the pump. Optionally, this obviates the need to use disposable parts.


The hybrid catheter blade can also be used for improved biopsy procedures enabling relative large sample to be collected for further histology analysis and thereby decrease sampling errors, which are associated with high risk in patients with BE or in gynecology and urology applications.


According to some embodiments, the hybrid catheter may further include imaging means to detect the required area that has to be treated and to monitor the process on-line, thereby enabling effective “focal therapy” according to the diseases severity from early stage such as Barrett's esophagus without dysplasia to more advanced disease with minimal complications, as it limits damage to the surrounding healthy tissue and avoid mucosal perforation. Similar considerations may apply in gynecology and urology applications. Means to obtain images of the working area may include, for example, commercial fiberscope such Medit INC F2.4 (2.4 mm 45 degrees FOV, with 30,000 pixels) or Olympus LF-2 (designed for tracheal intubation) that can be inserted into 5 mm tubes and includes a 1.5 mm channel for easier aspiration/instillation of fluids, providing images with 90 degrees field of view from >3 mm so the fiber can be placed accordingly. As disclosed hereinabove, the hybrid catheter may be combined with a commercial endoscope, such as a gastroscope preferably such that has enhanced imaging capabilities such a narrow band imaging (NBI) to detect the pathological areas with higher resolution. For example, an Olympus GIF-H180J model (or equivalent) may be used, which has a 9.9 mm diameter at the distal end so the hybrid catheter can be attached to the walls in a manner that it can be conveniently introduced to the body. This enables four-way angulations (210° up, 90° down, and 100° right/left) a 140° field of view and close-up high resolution image can be obtained as close as 2 mm from the tissue, so the laser blade catheter can be attached accordingly to the tip of the scope (relatively advanced in few mm at the front).


There is provided herein, in accordance with some embodiments, a hybrid catheter having a tip section having optical fibers for transmitting (pulse) laser radiation and inner and/or outer walls having facet that are sharp enough to complete the cutting and debulking (extracting) of leads initiated by the laser but not sharp enough to work alone in order to maintain the procedure's safety. Using the hybrid catheter allows decreasing the requirements from the laser and thus enables use of small solid state lasers, in such way that when the debulking of the leads is not completed by laser cutting the tissue surrounding the leads is performed mechanically (by sharp wall(s) and/or by a blade).


Reference is now made to FIGS. 13A-13C, which show cross section illustrations of three types of a hybrid catheter for pacemaker and ICD (Implantable Cardioverter Defibrillator) lead extraction.



FIG. 13A shows a cross section of hybrid catheter 2002 over lead 2000 which is to be extracted. Catheter 2002 has a tip section 2004, typically having a circular cross section. Tip section 2004 comprises an inner wall 2006 and an outer wall 2008, at least one of which having a sharp (for example tapered) distal end which thus function like blades. Optical fiber(s) 2010 are located between inner wall 2006 and outer wall 2008 and are configured to transmit laser radiation through the distal end of tip section 2004 (as marked by the arrows). The laser radiation modifies (e.g., ablate, partially ablate, weaken, cut, etc.) the tissue surrounding the lead and thereby preparing the tissue for penetration of the sharp distal edge of inner wall 2006 and outer wall 2008, such that walls are configured to cut through the modified tissue and thereby detach lead 2000 from the tissue.


According to some embodiment, the catheter may include means to hold the lead in order to extract it from the body. These embodiment aim to replace a complicated process known in the art wherein a lead locking device is inserted (e.g. Spectranetics Lead Locking Device (LLD®)) and then another catheter used for laser ablation (Spectranetics SLS® II) is inserted. Two examples of means for holding and retracting the lead are schematically illustrated in FIGS. 13B and 13C, in accordance with some embodiments.



FIG. 13B shows a cross section of hybrid catheter 3000 over lead 2000 which is to be extracted. Catheter 3000 may be similar to catheter 2002, but further includes a “donut shaped” balloon (3002/3004) connected to an inner wall of hybrid catheter 3000. When hybrid catheter 3000 is penetrating through the tissue surroundings lead 2000 the balloon is deflated (3002). When hybrid catheter 3000 is pulled out in order to extract lead 2000 the balloon is inflated (3004) and “holds” lead 2000 and thus assist in its extraction.



FIG. 13C shows a cross section of hybrid catheter 4000 over lead 2000 which is to be extracted. Catheter 4000 may be similar to catheter 2002, but further includes “grabbing elements” 4002, configured to allow smooth penetration of catheter 4000 through the tissue surroundings lead 2000 but to hold lead 2000 in a predetermined force when moving outside. According to some embodiments, the catheter may include means to release this holding in cases there is a need to retract the catheter without the lead.


In the description and claims of the application, each of the words “comprise” “include” and “have”, and forms thereof, are not necessarily limited to members in a list with which the words may be associated. In addition, where there are inconsistencies between this application and any document referenced or incorporated by reference, it is hereby intended that the present application controls.

Claims
  • 1. A method for removing an undesired tissue from a vessel using a catheter having a tip section and an aspiration lumen, wherein the catheter is operatively coupled to a laser system and an aspiration system, the method comprising: generating an aspiration force through the aspiration lumen to aspirate an undesired tissue within the vessel;transmitting a laser energy from the tip section, via at least one optical element, the at least one optical element being operatively coupled to the laser system when in use, wherein the laser energy is configured to modify a biological characteristic of the undesired tissue;detaching the undesired tissue from the vessel, wherein the tip section includes a cutter for detaching the undesired tissue from a wall of the vessel, and wherein distal ends of the at least one optical element and the cutter at an end of the tip section are substantially coplanar, with the cutter being positioned outside an optical path of the laser energy;monitoring treatment of the undesired tissue; andcontrolling detachment and removal of the undesired tissue based on the monitoring.
  • 2. The method of claim 1, the at least one optical element includes a plurality of optical fibers operatively coupled to the laser system when in use.
  • 3. The method of claim 1, wherein transmitting the laser energy from the tip section using the at least one optical element includes ablating the undesired tissue.
  • 4. The method of claim 2, wherein the plurality of optical fibers are positioned parallel to a central longitudinal axis of the tip section, and wherein generating the laser energy is at least partially distal to and outward of the tip section.
  • 5. The method of claim 1, wherein the laser energy has a wavelength of approximately 355 nm.
  • 6. The method of claim 1, wherein the laser energy has a pulse width of 10 nsec and a power level of 50 mJ/mm2.
  • 7. The method of claim 1, wherein the laser energy includes a plurality of pulses, and wherein an energy per pulse is 10-100 mJ and a pulse frequency is 10-100 Hz.
  • 8. The method of claim 1, further comprising: controlling the laser energy based on the monitoring.
  • 9. A method comprising: inserting a device having an aspiration lumen and a tip section into a body cavity, the tip section including a cutter formed at a distal edge of the tip section and a plurality of optical fibers positioned parallel to a central longitudinal axis of the tip section, wherein the plurality of optical fibers is operatively coupled to a laser system, wherein the cutter includes an inner blade and an outer blade, and wherein the plurality of optical fibers reside, at least in part, between the inner blade and the outer blade;activating the laser system to transmit laser energy to an undesired tissue within the body cavity using the plurality of optical fibers, thereby modifying a characteristic of the undesired tissue;advancing the device towards the modified undesired tissue such that the cutter detaches the modified undesired tissue from a wall of the body cavity; andactivating an aspiration device, wherein the aspiration device is configured to aspirate the modified undesired tissue through the aspiration lumen to remove the undesired material from the body cavity;monitoring treatment of the undesired tissue; andcontrolling detachment and removal of the undesired tissue based on the monitoring,wherein distal ends of the cutter and the plurality of optical fibers are substantially flush, with the cutter being positioned outside an optical path of the laser energy.
  • 10. The method of claim 9, wherein the laser energy has a wavelength of approximately 355 nm.
  • 11. The method of claim 9, wherein the laser energy is transmitted at 10 nsec pulses and a power level of 30-60 mJ/mm2.
  • 12. The method of claim 9, wherein the laser energy includes a plurality of pulses, and wherein an energy per pulse is 10-100 mJ and a pulse frequency is 10-100 Hz.
  • 13. The method of claim 9, further comprising: controlling treatment of the undesired tissue based on the monitoring.
  • 14. The method of claim 9, wherein transmission of the laser energy is at least partially distal to and outward of the tip section.
  • 15. The method of claim 9, wherein the tip section includes an inner wall and an outer wall and wherein the inner blade is positioned at a distal edge of the inner wall and the outer blade is positioned at a distal edge of the outer wall.
  • 16. The method of claim 15, wherein at least one of the inner wall and outer wall is coated with a material that provides a sharp edge thereto thereby forming the cutter.
  • 17. A method comprising: inserting a device having an aspiration lumen and a tip section into a body cavity, the tip section including an inner wall, an outer wall and a plurality of optical fibers positioned parallel to a central longitudinal axis of the tip section, and between the inner and outer walls, wherein the inner and outer walls are each coated with a material that provides a sharp edge thereto thereby forming a cutter;activating a laser system to transmit laser energy to an undesired tissue within the body cavity using the plurality of optical fibers, thereby modifying a characteristic of the undesired tissue to prepare the undesired material for detachment from the body cavity;advancing the device towards the modified undesired tissue such that the cutter detaches the modified undesired tissue from a wall of the body cavity; andactivating an aspiration device, wherein the aspiration device is configured to aspirate the modified undesired tissue through the aspiration lumen,monitoring treatment of the undesired tissue; andcontrolling treatment of the undesired tissue based on the monitoring,wherein distal ends of the cutter and the plurality of optical fibers are substantially flush, with the cutter being positioned outside an optical path of the laser energy.
  • 18. The method of claim 17, wherein transmission of the laser energy is at least partially distal to and outward of the tip section.
  • 19. The method of claim 1, wherein the tip section includes an inner wall and an outer wall, and the plurality of optical fibers are positioned between the inner wall and the outer wall.
  • 20. The method of claim 19, wherein the cutter includes an inner blade positioned at a distal edge of the inner wall and an outer blade positioned at a distal edge of the outer wall.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/436,650, filed Jun. 10, 2019, which is a continuation of U.S. patent application Ser. No. 15/649,234, filed Jul. 13, 2017 now U.S. Pat. No. 10,363,099), which is a continuation of U.S. patent application Ser. No. 14/001,633, filed Oct. 17, 2013 (now U.S. Pat. No. 9,730,756), which is the U.S. National Stage of International Application No. PCT/IL2012/000088, filed Feb. 23, 2012, which claims the benefit of U.S. Provisional Application Nos. 61/521,523, filed Aug. 9, 2011, and 61/446,145, filed Feb. 24, 2011, the contents of each of which are incorporated herein by reference in their entireties.

US Referenced Citations (883)
Number Name Date Kind
1706161 Hollnagel Mar 1929 A
2699770 Fourestier Jan 1955 A
3043910 Hicks, Jr. Jul 1962 A
3051035 Root Aug 1962 A
3051166 Hrair Aug 1962 A
3068742 Hicks, Jr. Dec 1962 A
3423581 Baer Jan 1969 A
3455625 Brumley Jul 1969 A
3572325 Seymour Mar 1971 A
3605750 Sheridan Sep 1971 A
3622743 Muncheryan Nov 1971 A
3641332 Reick Feb 1972 A
3643653 Takahashi Feb 1972 A
3678741 Burley Jul 1972 A
3704996 Borner Dec 1972 A
3710798 Bredemeier Jan 1973 A
3726272 Mori Apr 1973 A
3756688 Hudson Sep 1973 A
3768146 Braun Oct 1973 A
3780295 Kapron Dec 1973 A
3790791 Anderson Feb 1974 A
3796905 Maeda Mar 1974 A
3802440 Ziegler Apr 1974 A
3808549 Maurer Apr 1974 A
3832028 Kapron Aug 1974 A
3834391 Block Sep 1974 A
3834803 Tsukada Sep 1974 A
3843865 Nath Oct 1974 A
3846010 Love Nov 1974 A
3849947 Bunkoczy Nov 1974 A
3858577 Bass Jan 1975 A
3861781 Hasegawa Jan 1975 A
3866599 Johnson Feb 1975 A
3874783 Cole Apr 1975 A
3880452 Fields Apr 1975 A
3906221 Mercier Sep 1975 A
3910677 Becker Oct 1975 A
3920980 Nath Nov 1975 A
3932184 Cohen Jan 1976 A
3972585 Dalgleish Aug 1976 A
4005522 Dalgleish Feb 1977 A
4008948 Dalgleish Feb 1977 A
4087158 Lewis May 1978 A
4148554 Magnusson Apr 1979 A
4191446 Arditty Mar 1980 A
4233493 Nath Nov 1980 A
4273109 Enderby Jun 1981 A
4273127 Auth Jun 1981 A
4313431 Frank Feb 1982 A
4380365 Gross Apr 1983 A
4449535 Renault May 1984 A
4564011 Goldman Jan 1986 A
4573761 McLachlan Mar 1986 A
4578061 Lemelson Mar 1986 A
4592353 Daikuzono Jun 1986 A
4641912 Goldenberg Feb 1987 A
4654532 Hirschfeld Mar 1987 A
4660925 McCaughan, Jr. Apr 1987 A
4662368 Hussein May 1987 A
4666426 Aigner May 1987 A
4671273 Lindsey Jun 1987 A
4672961 Davies Jun 1987 A
4693244 Daikuzono Sep 1987 A
4693556 McCaughan, Jr. Sep 1987 A
4695697 Kosa Sep 1987 A
4697595 Breyer Oct 1987 A
4707134 McLachlan Nov 1987 A
4729763 Henrie Mar 1988 A
4732448 Goldenberg Mar 1988 A
4736743 Daikuzono Apr 1988 A
4740047 Abe Apr 1988 A
4743084 Manning May 1988 A
4773413 Hussein Sep 1988 A
4800876 Fox Jan 1989 A
4802650 Stricker Feb 1989 A
4812003 Dambach Mar 1989 A
4816670 Kitamura Mar 1989 A
4817601 Roth Apr 1989 A
4830460 Goldenberg May 1989 A
4832024 Boussignac May 1989 A
4834493 Cahill May 1989 A
4844062 Wells Jul 1989 A
4862887 Weber Sep 1989 A
4889129 Dougherty Dec 1989 A
4919508 Grace Apr 1990 A
4955882 Hakky Sep 1990 A
4966596 Kuntz Oct 1990 A
4968306 Huss Nov 1990 A
4968314 Michaels Nov 1990 A
4975925 Derrickson Dec 1990 A
4979797 Nemeth Dec 1990 A
4979939 Shiber Dec 1990 A
4985029 Hoshino Jan 1991 A
4988163 Cohen Jan 1991 A
4993412 Murphy-Chutorian Feb 1991 A
4995691 Purcell, Jr. Feb 1991 A
4998794 Holzman Mar 1991 A
5011254 Edwards Apr 1991 A
5011279 Auweter Apr 1991 A
5016964 Donnelly May 1991 A
5026366 Leckrone Jun 1991 A
5029588 Yock Jul 1991 A
5030201 Palestrant Jul 1991 A
5037180 Stone Aug 1991 A
5037421 Boutacoff Aug 1991 A
5041109 Abela Aug 1991 A
5042980 Baker Aug 1991 A
5053033 Clarke Oct 1991 A
5060557 Dunn Oct 1991 A
5074632 Potter Dec 1991 A
5093877 Aita Mar 1992 A
5100507 Cholewa Mar 1992 A
5112127 Carrabba May 1992 A
5129896 Hasson Jul 1992 A
5135531 Shiber Aug 1992 A
5146917 Wagnieres Sep 1992 A
5147353 Everett Sep 1992 A
5147354 Boutacoff Sep 1992 A
5151096 Khoury Sep 1992 A
5152744 Krause Oct 1992 A
5154708 Long Oct 1992 A
5157750 Grace Oct 1992 A
5164945 Long Nov 1992 A
5166756 McGee Nov 1992 A
5188632 Goldenberg Feb 1993 A
5188635 Radtke Feb 1993 A
5190536 Wood Mar 1993 A
5193526 Daikuzono Mar 1993 A
5196004 Sinofsky Mar 1993 A
5196005 Doiron Mar 1993 A
5207669 Baker May 1993 A
5222966 Perkins Jun 1993 A
5250045 Bohley Oct 1993 A
5253312 Payne Oct 1993 A
5254114 Reed, Jr. Oct 1993 A
5263951 Spears Nov 1993 A
5263952 Grace Nov 1993 A
5267979 Appling Dec 1993 A
5267993 Grace Dec 1993 A
5267995 Doiron Dec 1993 A
5269777 Doiron Dec 1993 A
5275622 Lazarus Jan 1994 A
5290275 Kittrell Mar 1994 A
5292311 Cope Mar 1994 A
5292320 Brown Mar 1994 A
5293872 Alfano Mar 1994 A
5300066 Manoukian Apr 1994 A
5306274 Long Apr 1994 A
5312396 Feld May 1994 A
5312399 Hakky May 1994 A
5315614 Grace May 1994 A
5321783 Nielson Jun 1994 A
5330465 Doiron Jul 1994 A
5342383 Thomas Aug 1994 A
5343543 Novak, Jr. Aug 1994 A
5346488 Prince Sep 1994 A
5349590 Amirkhanian Sep 1994 A
5350377 Winston Sep 1994 A
5352221 Fumich Oct 1994 A
5354294 Chou Oct 1994 A
5360416 Ausherman Nov 1994 A
5370649 Gardetto Dec 1994 A
5377683 Barken Jan 1995 A
5383199 Laudenslager Jan 1995 A
5395361 Fox Mar 1995 A
5400428 Grace Mar 1995 A
5401270 Gerhard Mar 1995 A
5402508 O'Rourke Mar 1995 A
5404218 Nave Apr 1995 A
5415633 Lazarus May 1995 A
5415653 Wardle May 1995 A
5415655 Fuller May 1995 A
5419312 Arenberg May 1995 A
5421928 Knecht Jun 1995 A
5423806 Dale Jun 1995 A
5425723 Wang Jun 1995 A
5428699 Pon Jun 1995 A
5429604 Hammersmark Jul 1995 A
5429617 Hammersmark Jul 1995 A
5432880 Diner Jul 1995 A
5445608 Chen Aug 1995 A
5456680 Taylor Oct 1995 A
5464395 Faxon Nov 1995 A
5466234 Loeb Nov 1995 A
5470330 Goldenberg Nov 1995 A
5484433 Taylor Jan 1996 A
5486170 Winston Jan 1996 A
5495541 Murray Feb 1996 A
5498258 Hakky Mar 1996 A
5499975 Cope Mar 1996 A
5509917 Cecchetti Apr 1996 A
5514128 Hillsman May 1996 A
5534000 Bruce Jul 1996 A
5536248 Weaver Jul 1996 A
5536265 Van Den Bergh Jul 1996 A
5562657 Griffin Oct 1996 A
5571098 Domankevitz Nov 1996 A
5624026 Chernoff Apr 1997 A
5631986 Frey May 1997 A
5643251 Hillsman Jul 1997 A
5643253 Baxter Jul 1997 A
5643257 Cohen Jul 1997 A
5653696 Shiber Aug 1997 A
5662646 Fumich Sep 1997 A
5688263 Hauptmann Nov 1997 A
5693029 Leonhardt Dec 1997 A
5693043 Kittrell Dec 1997 A
5695482 Kaldany Dec 1997 A
5695583 Van Den Bergh Dec 1997 A
5700243 Narciso, Jr. Dec 1997 A
5710626 O'Rourke Jan 1998 A
5717807 Theroux Feb 1998 A
5720894 Perry Feb 1998 A
5725521 Mueller Mar 1998 A
5728091 Payne Mar 1998 A
5754717 Esch May 1998 A
5764840 Wach Jun 1998 A
5769868 Yock Jun 1998 A
5782797 Schweich, Jr. Jul 1998 A
5807389 Gardetto Sep 1998 A
5810662 Van Becelaere Sep 1998 A
5817144 Gregory Oct 1998 A
5836940 Gregory Nov 1998 A
5836946 Diaz Nov 1998 A
5843073 Sinofsky Dec 1998 A
5868734 Soufiane Feb 1999 A
5878178 Wach Mar 1999 A
5897551 Everett Apr 1999 A
5908415 Sinofsky Jun 1999 A
5916210 Winston Jun 1999 A
5947959 Sinofsky Sep 1999 A
5951482 Winston Sep 1999 A
5951543 Brauer Sep 1999 A
5976124 Reiser Nov 1999 A
5989243 Goldenberg Nov 1999 A
5991404 Brahami Nov 1999 A
6013072 Winston et al. Jan 2000 A
6027450 Brown Feb 2000 A
6033398 Farley Mar 2000 A
6048349 Winston Apr 2000 A
6053809 Arceneaux Apr 2000 A
6056743 Ellis May 2000 A
6063093 Winston May 2000 A
6096011 Trombley, III Aug 2000 A
6102905 Baxter Aug 2000 A
6106515 Winston Aug 2000 A
6117125 Rothbarth Sep 2000 A
6126654 Giba Oct 2000 A
6139543 Esch Oct 2000 A
6152919 Hakky Nov 2000 A
6162214 Mueller Dec 2000 A
6164280 Everett Dec 2000 A
6179808 Boukhny Jan 2001 B1
6193676 Winston Feb 2001 B1
6206898 Honeycutt Mar 2001 B1
6210400 Hebert Apr 2001 B1
6228076 Winston May 2001 B1
6251100 Flock Jun 2001 B1
6258084 Goldman Jul 2001 B1
6263236 Kasinkas Jul 2001 B1
6270492 Sinofsky Aug 2001 B1
6270495 Palermo Aug 2001 B1
6283951 Flaherty Sep 2001 B1
6302875 Makower Oct 2001 B1
6344048 Chin Feb 2002 B1
6352549 Everett Mar 2002 B1
6375651 Grasso, III Apr 2002 B2
6394976 Winston May 2002 B1
6398777 Navarro Jun 2002 B1
6439944 La Fata Aug 2002 B1
6440125 Rentrop Aug 2002 B1
6447477 Burney Sep 2002 B2
6451010 Angeley Sep 2002 B1
6454790 Neuberger Sep 2002 B1
6463313 Winston Oct 2002 B1
6485485 Winston Nov 2002 B1
6514217 Selmon Feb 2003 B1
6522806 James, IV Feb 2003 B1
6539944 Watson Apr 2003 B1
6544230 Flaherty Apr 2003 B1
6547757 Kranz Apr 2003 B1
6547779 Levine Apr 2003 B2
6551302 Rosinko Apr 2003 B1
6554824 Davenport Apr 2003 B2
6555827 Kockott Apr 2003 B1
6561998 Roth May 2003 B1
6599277 Neubert Jul 2003 B2
6611720 Hata Aug 2003 B2
6628519 Umetsu Sep 2003 B2
6652803 Watanabe Nov 2003 B2
6663621 Winston Dec 2003 B1
6673064 Rentrop Jan 2004 B1
6673065 Veligdan Jan 2004 B1
6685648 Flaherty Feb 2004 B2
6692466 Chow Feb 2004 B1
6701044 Arbore Mar 2004 B2
6716210 Lin Apr 2004 B2
6746422 Noriega Jun 2004 B1
6752800 Winston Jun 2004 B1
6752803 Goldman Jun 2004 B2
6767338 Hawk Jul 2004 B2
6769433 Zikorus Aug 2004 B2
6772014 Coe Aug 2004 B2
6775447 Nicholson Aug 2004 B2
6796710 Yates Sep 2004 B2
6842639 Winston Jan 2005 B1
6845193 Loeb Jan 2005 B2
6852109 Winston Feb 2005 B2
6926692 Katoh Aug 2005 B2
6951554 Johansen Oct 2005 B2
6962584 Stone Nov 2005 B1
6962585 Poleo, Jr. Nov 2005 B2
6967767 Nicholson Nov 2005 B2
6970732 Winston Nov 2005 B2
6978783 Svendsen Dec 2005 B2
6986764 Davenport Jan 2006 B2
6986766 Caldera Jan 2006 B2
6989004 Hinchliffe Jan 2006 B2
7050692 Harlan May 2006 B2
7059330 Makower Jun 2006 B1
7063610 Mysker Jun 2006 B2
7063695 Nield Jun 2006 B2
7128735 Weston Oct 2006 B2
7141041 Seward Nov 2006 B2
7163535 Ryba Jan 2007 B2
7167622 Temelkuran Jan 2007 B2
7172576 Sawa Feb 2007 B2
7186252 Nobis Mar 2007 B2
7247162 Thornton Jul 2007 B1
7257302 Fermann Aug 2007 B2
7267674 Brucker Sep 2007 B2
7273469 Chan Sep 2007 B1
7273478 Appling Sep 2007 B2
7284981 Schmid Oct 2007 B2
7288087 Winston Oct 2007 B2
7303533 Johansen Dec 2007 B2
7331954 Temelkuran Feb 2008 B2
7357797 Ryba Apr 2008 B2
7377910 Katoh May 2008 B2
7379648 Brooks May 2008 B1
7381200 Katoh Jun 2008 B2
7391561 Di Teodoro Jun 2008 B2
7412132 Liu Aug 2008 B1
7430352 Di Teodoro Sep 2008 B2
7450618 Dantus Nov 2008 B2
7458967 Appling Dec 2008 B2
7479147 Honeycutt Jan 2009 B2
7483204 Harter Jan 2009 B2
7499756 Bowe Mar 2009 B2
7503914 Coleman Mar 2009 B2
7513886 Konstantino Apr 2009 B2
7519253 Islam Apr 2009 B2
7524289 Lenker Apr 2009 B2
7524316 Hennings Apr 2009 B2
7559329 Appling Jul 2009 B2
7563262 Winston Jul 2009 B2
7567596 Dantus Jul 2009 B2
7572254 Hebert Aug 2009 B2
7644715 Hayes Jan 2010 B2
7651503 Coe Jan 2010 B1
7666161 Nash Feb 2010 B2
7699790 Simpson Apr 2010 B2
7724787 Murison et al. May 2010 B2
7779842 Russo Aug 2010 B1
7787506 Jiang Aug 2010 B1
7809222 Hartl Oct 2010 B2
7811281 Rentrop Oct 2010 B1
7828793 Thompson Nov 2010 B2
7834331 Ben-Yakar Nov 2010 B2
7837677 Thompson Nov 2010 B2
7837678 Thompson Nov 2010 B2
7846153 Hebert Dec 2010 B2
7879011 Chang Feb 2011 B2
D634007 Zinger Mar 2011 S
7912554 Capuano Mar 2011 B2
7921854 Hennings Apr 2011 B2
7924892 Chuang Apr 2011 B2
7927784 Simpson Apr 2011 B2
7929579 Hohm Apr 2011 B2
7931659 Bose Apr 2011 B2
7942852 Mas May 2011 B2
7951094 Johansen May 2011 B2
7957790 Kleen Jun 2011 B2
7959608 Nash Jun 2011 B2
7963947 Kurth Jun 2011 B2
7963961 Thompson Jun 2011 B2
7963962 Thompson Jun 2011 B2
7975528 Hart Jul 2011 B2
7976533 Larsson Jul 2011 B2
7993359 Atwell Aug 2011 B1
8016784 Hayzelden Sep 2011 B1
8043285 Thompson Oct 2011 B2
8059274 Splinter Nov 2011 B2
8062226 Moore Nov 2011 B2
8073019 Liu Dec 2011 B2
8097012 Kagarise Jan 2012 B2
8100893 Dadisman Jan 2012 B2
8104483 Taylor Jan 2012 B2
8114429 Michal Feb 2012 B2
8128951 Michal Mar 2012 B2
8157747 Grata Apr 2012 B2
8182474 Winston May 2012 B2
8189971 Laurent May 2012 B1
8202268 Wells Jun 2012 B1
8238386 Limpert Aug 2012 B2
8246580 Hopkins Aug 2012 B2
8257722 Michal Sep 2012 B2
8291915 Farley Oct 2012 B2
8298215 Zinn Oct 2012 B2
8300669 Dantus Oct 2012 B2
8317779 Mirkov Nov 2012 B2
8321019 Esch Nov 2012 B2
8348844 Kunjan Jan 2013 B2
8350183 Vogel Jan 2013 B2
8353899 Wells Jan 2013 B1
8365741 Hennings Feb 2013 B2
8366735 Bose Feb 2013 B2
8413664 Appling Apr 2013 B2
8414568 Harlan Apr 2013 B2
8422134 Wu Apr 2013 B2
8425501 Appling et al. Apr 2013 B2
8428747 Coe Apr 2013 B2
8435235 Stevens May 2013 B2
8439874 Hertweck May 2013 B2
8460312 Bose Jun 2013 B2
8465467 Gao Jun 2013 B2
8465480 Winston Jun 2013 B2
8470010 Jakubowski Jun 2013 B2
8486051 Larsson Jul 2013 B2
8491925 Michal Jul 2013 B2
8500697 Kurth Aug 2013 B2
8512326 Shadduck Aug 2013 B2
8535360 Killian Sep 2013 B2
8545432 Renati Oct 2013 B2
8545468 Fabo Oct 2013 B2
8551067 Zinger Oct 2013 B2
8563023 Michal Oct 2013 B2
8587864 Harter Nov 2013 B2
8636726 Wells Jan 2014 B1
8636729 Esch Jan 2014 B2
8657785 Torrance Feb 2014 B2
8668665 Gerg Mar 2014 B2
8673332 Michal Mar 2014 B2
8684953 Cabiri Apr 2014 B2
8684994 Lev Apr 2014 B2
8696695 Patel Apr 2014 B2
8702773 Keeler Apr 2014 B2
8721634 Esch May 2014 B2
8728066 Shadduck May 2014 B2
8734825 Michal May 2014 B2
8752598 Denenburg Jun 2014 B2
8753325 Lev Jun 2014 B2
8758333 Harlan Jun 2014 B2
8767287 Clowes Jul 2014 B2
8784394 Kerr Jul 2014 B2
8808074 Kim Aug 2014 B2
8814922 Hennings Aug 2014 B2
8840606 Appling Sep 2014 B2
8852145 Denenburg Oct 2014 B2
8852165 MacKay, II Oct 2014 B2
8852178 Thompson Oct 2014 B2
8855151 Harter Oct 2014 B2
8861075 Dantus Oct 2014 B2
8864754 Appling Oct 2014 B2
8864755 Appling Oct 2014 B2
8881735 Mitchell Nov 2014 B2
8887733 Appling Nov 2014 B2
D720451 Denenburg Dec 2014 S
8905994 Lev Dec 2014 B1
8915896 Sanders Dec 2014 B2
8920402 Nash Dec 2014 B2
8953648 Ishaaya Feb 2015 B2
8956376 Alvarez Feb 2015 B2
8961551 Taylor Feb 2015 B2
8979792 Lev Mar 2015 B2
8979828 Fix Mar 2015 B2
8998875 Lev Apr 2015 B2
8998936 Alvarez Apr 2015 B2
9028520 Taylor May 2015 B2
9034362 Michal May 2015 B2
9044829 Crist Jun 2015 B2
9050127 Bonnette Jun 2015 B2
9066736 Islam Jun 2015 B2
9066742 Splinter Jun 2015 B2
D734868 Gilboa Jul 2015 S
9119656 Bose Sep 2015 B2
9119907 Sherman Sep 2015 B2
9125562 Spencer Sep 2015 B2
9132211 Michal Sep 2015 B2
D740946 Szabo Oct 2015 S
9162038 Rottenberg Oct 2015 B2
D742520 Szabo Nov 2015 S
D742521 Szabo Nov 2015 S
D742522 Szabo Nov 2015 S
9198968 Michal Dec 2015 B2
9199011 Locke Dec 2015 B2
9216056 Datta Dec 2015 B2
9220523 Taylor Dec 2015 B2
D748266 Szabo Jan 2016 S
9238122 Malhi Jan 2016 B2
9248221 Look Feb 2016 B2
9254175 Winston Feb 2016 B2
9283039 Harlan Mar 2016 B2
9283040 Hendrick Mar 2016 B2
9287677 Clowes Mar 2016 B2
9289173 Splinter Mar 2016 B2
9289226 Taylor Mar 2016 B2
9291663 Grace Mar 2016 B2
9295373 Torrance Mar 2016 B2
D753289 Shimon Apr 2016 S
D753290 Shimon Apr 2016 S
9308047 Taylor Apr 2016 B2
9320530 Grace Apr 2016 B2
9333007 Escudero May 2016 B2
9339337 Fix May 2016 B2
9345508 Hendrick May 2016 B2
9345510 Patel May 2016 B2
9358042 Magee Jun 2016 B2
9368931 Bragagna Jun 2016 B2
9408665 Sauro Aug 2016 B2
9408998 Alvarez Aug 2016 B2
9413896 Bowe Aug 2016 B2
9421035 Hendrick Aug 2016 B2
9421065 Splinter Aug 2016 B2
9456672 Condon Oct 2016 B2
9456872 Hendrick Oct 2016 B2
9510854 Mallaby Dec 2016 B2
D775728 Cavada et al. Jan 2017 S
9566116 Winston Feb 2017 B2
9603618 Grace Mar 2017 B2
9622819 Mitchell Apr 2017 B2
9623211 Hendrick Apr 2017 B2
9636482 McDaniel May 2017 B2
9642646 Patel May 2017 B2
9649158 Datta May 2017 B2
9649159 Keeler May 2017 B2
9655633 Leynov May 2017 B2
9662478 Browd May 2017 B2
9668765 Grace Jun 2017 B2
9668766 Rottenberg Jun 2017 B2
9675371 Shimon Jun 2017 B2
9675415 Varghese Jun 2017 B2
9676167 Marjanovic Jun 2017 B2
9678405 Mironov Jun 2017 B2
9681882 Garrison Jun 2017 B2
9694118 Esnouf Jul 2017 B2
9724122 Hendrick Aug 2017 B2
9730756 Ben Oren Aug 2017 B2
9731098 Hendrick Aug 2017 B2
9731113 Grace Aug 2017 B2
9757200 Magee et al. Sep 2017 B2
9760518 Grossman Sep 2017 B2
9763692 Bowe Sep 2017 B2
9770536 Speck Sep 2017 B2
9774161 Zach Sep 2017 B2
9775969 Alvarez Oct 2017 B2
9795505 Yu Oct 2017 B2
9801650 Taylor Oct 2017 B2
9803973 Sajedi Oct 2017 B1
9808275 Taylor Nov 2017 B2
9808277 Nash Nov 2017 B2
9814862 Alvarez Nov 2017 B2
9820761 Garrison Nov 2017 B2
9821090 Triffo Nov 2017 B2
9827055 Hendrick Nov 2017 B2
9844410 Mitchell Dec 2017 B2
9844485 Locke Dec 2017 B2
9848952 Khanna Dec 2017 B2
9855100 Splinter Jan 2018 B2
9855374 Sherman Jan 2018 B2
9864140 Adler Jan 2018 B2
9878399 Liu Jan 2018 B2
9882342 Zach Jan 2018 B2
9883877 Look Feb 2018 B2
9883885 Hendrick Feb 2018 B2
9884184 Triffo Feb 2018 B2
9895473 Look Feb 2018 B2
9907614 Grace Mar 2018 B2
9907615 Keeler Mar 2018 B2
9913688 Karavitis Mar 2018 B1
9918729 Taylor Mar 2018 B2
9925316 Sanders Mar 2018 B2
9925366 Grace Mar 2018 B2
9925371 Grace Mar 2018 B2
9931166 Sauro Apr 2018 B2
9937005 Hendrick Apr 2018 B2
9949753 Bowe Apr 2018 B2
9958385 Manassen May 2018 B2
9962527 Laudenslager May 2018 B2
9980743 Grace May 2018 B2
9999468 Chalfant Jun 2018 B2
10010657 Torrance Jul 2018 B2
10039569 Hendrick Aug 2018 B2
10046093 Michal Aug 2018 B2
10052129 Grace Aug 2018 B2
10079466 Ishaaya Sep 2018 B2
10080608 Datta Sep 2018 B2
10085883 Auld Oct 2018 B2
10092357 Fix Oct 2018 B2
10092363 Magee Oct 2018 B2
10105533 Grace Oct 2018 B2
10111709 Taylor Oct 2018 B2
10117970 Michal Nov 2018 B2
10135225 Weichmann Nov 2018 B2
10136913 Grace Nov 2018 B2
10141709 Ishaaya Nov 2018 B2
10149718 Fiser Dec 2018 B2
10166375 Browd Jan 2019 B2
10183150 McDaniel Jan 2019 B2
10183151 Alvarez Jan 2019 B2
10201315 Peatfield Feb 2019 B2
10201387 Grace Feb 2019 B2
10206745 Hendrick Feb 2019 B2
10219819 Grace Mar 2019 B2
10226263 Look Mar 2019 B2
10236952 Sadot Mar 2019 B1
10245107 Sierra Apr 2019 B2
10258792 Archuleta Apr 2019 B2
10265520 Grace Apr 2019 B2
10271904 Islam Apr 2019 B2
10285726 Nguyen May 2019 B2
10305244 Sierra May 2019 B2
10321931 Aljuri Jun 2019 B2
10342902 Bagwell Jul 2019 B2
10363398 Gerrans Jul 2019 B2
10391275 Burnett Aug 2019 B2
10405924 Bowe Sep 2019 B2
10499944 Mallaby Dec 2019 B2
10531883 Deville Jan 2020 B1
10603415 Look Mar 2020 B2
10702292 Look Jul 2020 B2
10716583 Look Jul 2020 B2
10716880 Culbert Jul 2020 B2
10722253 Deville Jul 2020 B2
10765592 Locke Sep 2020 B2
10772683 Zabar Sep 2020 B2
10792103 Zabar Oct 2020 B2
10835647 Sherman Nov 2020 B2
10835711 Yang Nov 2020 B2
10993731 Leynov May 2021 B2
11051832 Look Jul 2021 B2
11090117 Zabar Aug 2021 B2
11096712 Teigen Aug 2021 B2
11197683 Teigen Dec 2021 B1
11247030 Browd Feb 2022 B2
11259821 Buck Mar 2022 B2
11317787 Hillman May 2022 B2
11337712 Teigen May 2022 B2
11357951 Burnett Jun 2022 B2
11369435 Khan Jun 2022 B2
11400255 Chou Aug 2022 B1
11406402 Deville Aug 2022 B2
11432835 Shaffer Sep 2022 B2
11464528 Brady Oct 2022 B2
11471582 Yee Oct 2022 B2
11490909 Look Nov 2022 B2
11497521 Mallaby Nov 2022 B2
11547426 Deville Jan 2023 B2
11835707 Liang Dec 2023 B2
20010001314 Davison May 2001 A1
20010016739 Goldman Aug 2001 A1
20010016749 Blatter Aug 2001 A1
20020016624 Patterson Feb 2002 A1
20020045811 Kittrell Apr 2002 A1
20020072680 Schock Jun 2002 A1
20020095087 Mourad Jul 2002 A1
20020173811 Tu Nov 2002 A1
20020183729 Farr Dec 2002 A1
20030009157 Levine Jan 2003 A1
20030050686 Raeder-Devens Mar 2003 A1
20030078568 Caldera Apr 2003 A1
20030120256 Lary Jun 2003 A1
20030125709 Eidenschink Jul 2003 A1
20030125719 Furnish Jul 2003 A1
20030171691 Ward Sep 2003 A1
20030181823 Gatto Sep 2003 A1
20030181847 Bruno-Raimondi Sep 2003 A1
20030181938 Roth Sep 2003 A1
20030191460 Hobbs Oct 2003 A1
20030199860 Loeb Oct 2003 A1
20030199960 Paskar Oct 2003 A1
20040044337 Shafirstein Mar 2004 A1
20040093044 Rychnovsky May 2004 A1
20040102766 Poleo May 2004 A1
20040138562 Makower Jul 2004 A1
20040142654 Stammer Jul 2004 A1
20040162516 Mandrusov Aug 2004 A1
20040193055 Field Sep 2004 A1
20040236228 Stoltz Nov 2004 A1
20050015123 Paithankar Jan 2005 A1
20050020901 Belson Jan 2005 A1
20050107738 Slater May 2005 A1
20050113798 Slater May 2005 A1
20050131400 Hennings Jun 2005 A1
20050177132 Lentz Aug 2005 A1
20050187537 Loeb Aug 2005 A1
20050203497 Speeg Sep 2005 A1
20050244101 Kitabayashi Nov 2005 A1
20050251116 Steinke Nov 2005 A1
20050288655 Root Dec 2005 A1
20060069417 Farley Mar 2006 A1
20060095015 Hobbs May 2006 A1
20060095059 Bleich May 2006 A1
20060106338 Chang May 2006 A1
20060137345 Cho Jun 2006 A1
20060142747 Appling Jun 2006 A1
20060149218 Slater Jul 2006 A1
20060189967 Masotti Aug 2006 A1
20060229515 Sharareh Oct 2006 A1
20060241495 Kurtz Oct 2006 A1
20060241572 Zhou Oct 2006 A1
20060253112 Suarez Nov 2006 A1
20060264905 Eskridge Nov 2006 A1
20070016177 Vaynberg Jan 2007 A1
20070073160 Imam Mar 2007 A1
20070073268 Goble Mar 2007 A1
20070073278 Johnson Mar 2007 A1
20070123846 Hennings May 2007 A1
20070129706 Katoh Jun 2007 A1
20070135791 Slater Jun 2007 A1
20070149985 Cole Jun 2007 A1
20070167937 Brown Jul 2007 A1
20070179485 Yeik Aug 2007 A1
20070179486 Welch Aug 2007 A1
20070179575 Esch Aug 2007 A1
20070208400 Nadkarni Sep 2007 A1
20070270688 Gelbart Nov 2007 A1
20070299404 Katoh Dec 2007 A1
20070299431 Jakubowski Dec 2007 A1
20080015559 Appling Jan 2008 A1
20080071333 Hayes Mar 2008 A1
20080082091 Rubtsov Apr 2008 A1
20080114428 Trembly May 2008 A1
20080119869 Teague May 2008 A1
20080146918 Magnin Jun 2008 A1
20080154257 Sharareh Jun 2008 A1
20080154293 Taylor Jun 2008 A1
20080177186 Slater Jul 2008 A1
20080188843 Appling Aug 2008 A1
20080188910 Spaide Aug 2008 A1
20080200873 Espinosa Aug 2008 A1
20080208180 Cartier Aug 2008 A1
20080221560 Arai Sep 2008 A1
20080249399 Appling Oct 2008 A1
20080262465 Zinger Oct 2008 A1
20080275445 Kelly Nov 2008 A1
20080300583 Foley Dec 2008 A1
20080300662 Taylor Dec 2008 A1
20080319418 Chong Dec 2008 A1
20090018486 Goren Jan 2009 A1
20090018603 Mitelberg Jan 2009 A1
20090082760 Zinn Mar 2009 A1
20090105654 Kurth Apr 2009 A1
20090125007 Splinter May 2009 A1
20090163899 Burton Jun 2009 A1
20090182281 Kurth Jul 2009 A1
20090209907 Grata Aug 2009 A1
20090234344 Lavender Sep 2009 A1
20090234378 Escudero Sep 2009 A1
20090247823 Yamamoto Oct 2009 A1
20090254078 Just Oct 2009 A1
20090264875 Appling Oct 2009 A1
20090299351 Dadisman Dec 2009 A1
20100016857 McKenna Jan 2010 A1
20100057056 Gurtner Mar 2010 A1
20100069897 Spikker Mar 2010 A1
20100125253 Olson May 2010 A1
20100152720 Sauro Jun 2010 A1
20100168572 Sliwa Jul 2010 A1
20100168823 Strisower Jul 2010 A1
20100191178 Ross Jul 2010 A1
20100198150 Michal Aug 2010 A1
20100198240 Simpson Aug 2010 A1
20100198247 Chang Aug 2010 A1
20100210995 Jakubowski Aug 2010 A1
20100234925 Harris Sep 2010 A1
20100280504 Manzke et al. Nov 2010 A1
20100286791 Goldsmith Nov 2010 A1
20100296531 Hohm Nov 2010 A1
20100305475 Hinchliffe Dec 2010 A1
20100305715 Mathis Dec 2010 A1
20100312263 Moberg Dec 2010 A1
20100318067 Klima Dec 2010 A1
20110034922 Thompson Feb 2011 A1
20110060300 Weig Mar 2011 A1
20110134523 Wu Jun 2011 A1
20110172586 Hennings Jul 2011 A1
20110213446 Tucek Sep 2011 A1
20110251519 Romoscanu Oct 2011 A1
20110270238 Rizq Nov 2011 A1
20120065490 Zharov Mar 2012 A1
20120109191 Marano, Jr. May 2012 A1
20120130415 Tal May 2012 A1
20120265183 Tulleken Oct 2012 A1
20120271170 Emelianov Oct 2012 A1
20130005236 Kim Jan 2013 A1
20130096545 Laudenslager Apr 2013 A1
20130131643 Parodi May 2013 A1
20130131644 Parodi May 2013 A1
20130197306 Armand Aug 2013 A1
20130211379 Clair Aug 2013 A1
20130231660 Edwards Sep 2013 A1
20130261614 Appling Oct 2013 A1
20130274674 Fischell Oct 2013 A1
20130304034 Cabiri Nov 2013 A1
20130310680 Werahera Nov 2013 A1
20130345541 Nau, Jr. Dec 2013 A1
20140031800 Ben Oren Jan 2014 A1
20140052114 Ben-Oren Feb 2014 A1
20140081292 Moll Mar 2014 A1
20140133814 Stevens May 2014 A1
20140180034 Hoseit Jun 2014 A1
20140188062 James Jul 2014 A1
20140263207 Liu Sep 2014 A1
20140276682 Hendrick Sep 2014 A1
20140276689 Grace Sep 2014 A1
20140343482 MacKay Nov 2014 A1
20140358134 Appling Dec 2014 A1
20150038953 Varghese Feb 2015 A1
20150057648 Swift Feb 2015 A1
20150164573 Delaney Jun 2015 A1
20150238091 Iyer Aug 2015 A1
20150320480 Cosman, Jr. Nov 2015 A1
20150359595 Ben Oren et al. Dec 2015 A1
20160135883 Herscher May 2016 A1
20170100142 Look Apr 2017 A1
20170246444 Domatch Aug 2017 A1
20180028794 Browd Feb 2018 A1
20180207397 Look Jul 2018 A1
20190015157 Grace Jan 2019 A1
20190216476 Barry Jul 2019 A1
20190290815 Antonicelli Sep 2019 A1
20190336732 Laudenslager Nov 2019 A1
20190343445 Burnett Nov 2019 A1
20200009301 Yee Jan 2020 A1
20200015840 Mallaby Jan 2020 A1
20200022711 Look Jan 2020 A1
20200179576 Wood Jun 2020 A1
20200179578 Look Jun 2020 A1
20200206457 Boling Jul 2020 A1
20200281610 Look Sep 2020 A1
20200289722 Culbert Sep 2020 A1
20200297362 Deville Sep 2020 A1
20200337772 Ben-Oren Oct 2020 A1
20200367917 Teigen Nov 2020 A1
20200397957 Teigen Dec 2020 A1
20210038306 McLoughlin Feb 2021 A1
20210069467 Garrison Mar 2021 A1
20210093756 Sherman Apr 2021 A1
20210109340 Kaicheng Apr 2021 A1
20210128182 Teigen May 2021 A1
20210315598 Buck Oct 2021 A1
20220008090 Look Jan 2022 A1
20220031930 Downey Feb 2022 A1
20220096104 Ogle Mar 2022 A1
20220152345 Simiele May 2022 A1
20220152346 Burnett May 2022 A1
20220176031 Cheng Jun 2022 A1
20220193366 Cheng Jun 2022 A1
20220211437 Ben-Oren Jul 2022 A1
20220218365 Deville Jul 2022 A1
20220257268 Culbert Aug 2022 A1
20220280171 Teigen Sep 2022 A1
20220338887 Nair Oct 2022 A1
20220339338 Nair Oct 2022 A1
20220339339 Nair Oct 2022 A1
20220378443 Look Dec 2022 A1
20220378450 Culbert Dec 2022 A1
20220379081 Look Dec 2022 A1
20220379082 Look Dec 2022 A1
20220379083 Look Dec 2022 A1
20220379084 Look Dec 2022 A1
20220379085 Look Dec 2022 A1
20220379086 Look Dec 2022 A1
20220387052 Look Dec 2022 A1
20220387752 Look Dec 2022 A1
20220387753 Look Dec 2022 A1
20230026412 Teigen Jan 2023 A1
20230099283 Deville Mar 2023 A1
20230100426 Deville Mar 2023 A1
20230301708 Mickelsen Sep 2023 A1
20230329780 Liu Oct 2023 A1
20230408329 Zabar Dec 2023 A1
Foreign Referenced Citations (43)
Number Date Country
1326800 Feb 1994 CA
3017252 Dec 2019 CA
3105728 Jan 2020 CA
1049287 Feb 1991 CN
1261774 Aug 2000 CN
2713994 Aug 2005 CN
101170959 Apr 2008 CN
101795630 Aug 2010 CN
112533550 Mar 2021 CN
8905642 Aug 1989 DE
60316175 May 2008 DE
0311295 Apr 1989 EP
0341943 Nov 1989 EP
1567082 Aug 2005 EP
1610855 Jan 2006 EP
1709987 Oct 2006 EP
2226031 Sep 2010 EP
2399507 Dec 2011 EP
3025175 Jun 2016 EP
3423124 Oct 2019 EP
3806757 May 2022 EP
1533204 Nov 1978 GB
224434 Dec 2016 IL
H01178011 Jul 1989 JP
2021532850 Dec 2021 JP
20210035811 Apr 2021 KR
9214515 Sep 1992 WO
9509575 Apr 1995 WO
9834673 Aug 1998 WO
0245601 Jun 2002 WO
WO-03057060 Jul 2003 WO
2004021886 Mar 2004 WO
2004043280 May 2004 WO
2007125638 Nov 2007 WO
2008124790 Oct 2008 WO
02011107117 Sep 2011 WO
2012114333 Aug 2012 WO
2012114334 Aug 2012 WO
2012151396 Nov 2012 WO
2013172970 Nov 2013 WO
2014118738 Aug 2014 WO
2017155994 Sep 2017 WO
2018019829 Feb 2018 WO
Non-Patent Literature Citations (132)
Entry
Albagli, D., et al., Time Dependence of Laser-Induced Surface Breakdown in Fused Silica at 355nm in the Nanosecond Regime, SPIE vol. 1441, Laser Induced Damage in Optical Materials, 1990, 8 pages.
Alexander (1991) Tissue pathologies uncovered by spectral analysis. J Clin Laser Med Surg 9(4): 238-241.
Almeida, et al, RF Endovenous ClosureFAST Versus Laser Ablation for the Treatment of Great Saphenous Reflux: A Multicenter, Single-blinded, Randomized Study, J Vase Interv Radiol 2009, 20:752-759.
Ambrosini, V. et al., Excimer laser in acute myocardial infarction: Single centre experience on 66 patients, International Journal of Cardiology 127 (2008) 98-102.
Chinese Office Action for App. No. CN2017103395497, dated Apr. 3, 2021, 7 pages.
Chong, et al, Technical Tip: Cold Saline Infiltration Instead of Local Anaesthetic in Endovenous Laser Treatment, Phlebology vol. 21 No. 2, 2006, oo 88-89.
Coe, M. Sean, et al., Excimer Laser Lead Extraction Catheter with Increased Laser Parameters, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems Xi, R. Rox Anderson et al., Editors, Proceedings of SPIE vol. 4244 (2001), 8 pages.
Cordis® Outback® Re-Entry Catheter, Chronic Total Occlusion (CTO) Technologies brochure, Dec. 2008.
Corrected Notice of Allowance dated Nov. 5, 2021 for U.S. Appl. No. 16/189,297 (pp. 1-5).
Cummings et al., (2004) Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 89(6): 2608-15.
Dimatteo, et al.(2010) EUS-guided Nd: YAG laser ablation of normal pancreatic tissue: a pilot study in a pig model, Gastrointest. Endosc. 72(2): 358-63.
Doganci, et al., Comparison of 980 nm Laser and Bare-tip Fibre with 1470 nm Laser and Radial Fibre in the Treatment of Great Saphenous Vein Varicosities: A Prospective Randomised Clinical Trial, Eur J Vase Endovasc Surg. 2010, pp. 254-259.
Du, etal, PhotochemCAD: A Computer-Aided Design and Reseach Tool in Photochemistry, Photochemisty and Photobiology, 1998, 68(2), pp. 141-142.
Dunst, et al., Diffuse Phlegmonous Phlebitis After Endovenous Laser Treatment of the Greater Saphenous Vein, Journal of Vascular Surgery, vol. 43 No. 5, 2006, pp. 1056-1058.
Elias, et al., Treating the Small Saphenous Vein, Endovascular Today, Aug. 2008, pp. 60-64.
Endovascular Today, Supplement to Endovascular Today, Nov./Dec. 2004, pp S1-S35.
English Language Version of the Technical Report Issued for Brazilian Patent App. No. BR1120130214635, dated Jan. 4, 2021, 5 pages.
Esenaliev, R.O., et al., Laser Ablation of Atherosclerotic Blood Vessel Tissue Under Various Irradiation Conditions, IEEE Transactions on Biomedical Engineering, vol. 36, No. 12, (Dec. 1989) pp. 1188-1194.
European Patent Office Communication pursuant to Article 94(3) EPC for App. No. EP12750139.3, dated Jun. 11, 2021, 5 pages.
European Search Opinion, PCT/IB2014058688, Dec. 2, 2016, 10 pages.
European Search Report, EP19177412, Oct. 28, 2019, 3 pages.
European Search Report, PCT/IL2015050480, Apr. 13, 2017, 7 pages.
Fleischer and Sharma (2008) Endoscopic Ablation of Barrett's Esophagus Using the Halo System. Dig Dis 26(4): 280-284.
Fleischer and Sharma (2009) Endoscopic Ablation of Barrett's Esophagus Using the Halo® System. Dig Dis 26(4): 280-284.
Fleischer and Sharma, Endoscopic Ablation of Barrett's Esophagus Using the HALO® System. Mönkemüller K, Wilcox CM, Muñoz-Navas M (eds):Interventional and Therapeutic Gastrointestinal Endoscopy. Front Gastrointest Res. Basel, Karger, 2010, vol. 27, pp. 140-146.
Grundfest et al., (1985) Pulsed ultraviolet lasers and the potential for safe laser angioplasty. Am J Surg 150(2): 220-226.
Herzog, Amir et al., Spatial-coherence effect on damage occurrence in multimode optical fibers using nanosecond pulses, Advanced Photonics © 2014 OSA, 1 page.
Hongbao, Ma et al., Interaction of excimer laser with blood components and thrombosis, Life Science Journal, vol. 5, Mo 3, 2008, 8 pages.
International Preliminary Report on Patentability, PCT/IB2014/058688, Apr. 8, 2015, 7 pages.
International Preliminary Report on Patentability, PCT/IL2012/000088, Aug. 27, 2013, 10 pages.
International Preliminary Report on Patentability, PCT/IL2012/000089, Aug. 27, 2013, 9 pages.
International Preliminary Report on Patentability, PCT/IL2015/050480, Nov. 8, 2016, 8 pages.
International Preliminary Report on Patentability, PCT/IL2015/050529, Nov. 22, 2016, 6 pages.
International Preliminary Report on Patentability, PCT/IL2017/050498, Nov. 6, 2018, 7 pages.
International Search Report 03763292_SESR, dated Jan. 28, 2010.
International Search Report 04256733 ESR, dated Jan. 14, 2005.
International Search Report EP03252158_AESR dated Aug. 29, 2003, 1 page.
International Search Report for PCT/IL2015/050480 Completed Oct. 19, 2015; Mailed Oct. 21, 2015, 6 pages.
International Search Report PCT-US-03-21213 ISR, dated Mar. 29, 2004.
International Search Report PCT-US-08-059791 IPRP, dated Nov. 4, 2008.
International Search Report PCT-US-08-059791 ISR, dated Nov. 4, 2008.
International Search Report PCT-US-08-059791 WOSA, Nov. 4, 2008.
International Search Report PCT/IL2017/050498 Completed Aug. 15, 2017; Mailed Sep. 10, 2017, 4 pages.
International Search Report, PCT/IB2014/058688, Jun. 15, 2014, 5 pages.
International Search Report, PCT/IL2012/000088, Jul. 17, 2012, 2 pages.
International Search Report, PCT/IL2012/000089, Jul. 13, 2012, 2 pages.
International Search Report, PCT/IL2015/050529, Sep. 16, 2015, 5 pages.
International Search Report, PCT/IL2017/050498, Nov. 17, 2017, 4 pages.
Jackson (2009) High-power and highly efficient diode-cladding-pumped holmium-doped flouride fiber laster operating at 2.94 microm. Opt Lett 34(15):2327-2329.
Jackson et al., (2007) Directly diode-pumped holmium fiber lasers. Optics Letters 32(17): 2496-2498.
Jansen, E. Duco et al., Excimer, Ho: YAG, and Q-switched Ho: YAG ablation of aorta: a comparison of temperatures and tissue damage in vitro, Applied Optics, vol. 32, No. 4, Feb. 1, 1993, 9 pages.
Kabnick, et al, EVL Ablation Using Jacket-Tip Laser Fibers, Endovascular Today, Jul. 2009, pp. 77-81.
Leopardi, et al, Systematic Review of Treatments for Varicose Veins, Ann Vase Surg 2009: 23:264-276.
Litvack, et al, (1988) Pulsed laser angioplasty: wavelength power and energy dependencies relevant to clinical application. Lasers Surg Med 8(1): 60-65.
MacKay, et al., Saphenous Vein Ablation, Endovascular Today, Mar. 2006, pp. 44-48.
Memetoglu, et al, Combination Technique of Tumescent Anesthesia During Endovenous Laser Therapy of Saphenous Vein Insufficiency, Interactive Cardiovascular and Thoracic Surgery 11, 2010, pp. 774-778.
Min, et al, Endovenous Laser Treatment of Saphenous Vein Reflux: Long-Term Results, J Vase Interv Radiol 2003, 14:991-996.
Min, et al, Endovenous Laser Treatment of the Incompetent Greater Saphenous Vein, J Vase Interv Radiol 2001, 12:1167-1171.
Murphy-Chutorian et al., (1985) Selective absorption of ultraviolet laser energy by human atherosclerotic plaque treated with tetracycline. Am J Cardiol 55(11): 1293-1297.
Neev, Joseph, Ph. D., Two-Lasers Assisted Ablation: A Method for Enhancing Conventional Laser Ablation of Materials, Lasers in Surgery and Medicine 19:130-134 (1996).
Notice of Allowance dated Oct. 5, 2022 for U.S. Appl. No. 16/436,650 (pp. 1-8).
Notice of Allowance dated Dec. 21, 2022 for U.S. Appl. No. 16/094,137 (pp. 1-7).
Notice of Allowance dated Apr. 13, 2021 for U.S. Appl. No. 17/123,205 (pp. 1-8).
Notice of Allowance dated Aug. 10, 2020 for U.S. Appl. No. 16/655,864 (pp. 1-9).
Notice of Allowance dated Aug. 6, 2020 for U.S. Appl. No. 16/592,725 (pp. 1-9).
Notice of Allowance dated Jul. 26, 2021 for U.S. Appl. No. 16/189,297 (pp. 1-8).
Notice of Allowance dated Jun. 10, 2022 for U.S. Appl. No. 16/436,650 (pp. 1-7).
Notice of Allowance dated May 10, 2021 for U.S. Appl. No. 17/076,032 (pp. 1-8).
Office Action dated Oct. 4, 2022 for U.S. Appl. No. 14/764,180 (pp. 1-21).
Office Action dated Dec. 28, 2022 for U.S. Appl. No. 16/839,523 (pp. 1-11).
Office Action dated Apr. 15, 2021 for U.S. Appl. No. 16/189,297 (pp. 1-8).
Office Action dated Apr. 29, 2020 for U.S. Appl. No. 16/094,137 (pp. 1-12).
Office Action dated Aug. 3, 2021 for U.S. Appl. No. 16/436,650 (pp. 1-11).
Office Action dated Dec. 11, 2020 for U.S. Appl. No. 16/189,297 (pp. 1-7).
Office Action dated Feb. 15, 2022 for U.S. Appl. No. 16/436,650 (pp. 1-13).
Office Action dated Feb. 24, 2021 for U.S. Appl. No. 17/123,205 (pp. 1-4).
Office Action dated Jan. 31, 2022 for U.S. Appl. No. 16/436,650 (pp. 1-11).
Office Action dated Jul. 13, 2022 for U.S. Appl. No. 16/839,523 (pp. 1-9).
Office Action dated Jun. 9, 2020 for U.S. Appl. No. 16/189,297 (pp. 1-10).
Office Action dated Jun. 26, 2020 for U.S. Appl. No. 14/764,180 (pp. 1-16).
Office Action dated Mar. 2, 2021 for U.S. Appl. No. 16/436,650 (pp. 1-16).
Office Action dated Mar. 23, 2021 for U.S. Appl. No. 17/123,205 (pp. 1-3).
Office Action dated May 6, 2022 for U.S. Appl. No. 14/764,180 (pp. 1-16).
Office Action dated May 28, 2021 for U.S. Appl. No. 16/366,434 (pp. 1-12).
Office Action dated Sep. 2, 2020 for U.S. Appl. No. 16/436,650 (pp. 1-19).
Office Action dated Sep. 30, 2021 for U.S. Appl. No. 14/764,180 (pp. 1-16).
Office Action dated Sep. 9, 2020 for U.S. Appl. No. 16/094,137 (pp. 1-11).
Oraevsky, Alexander A., Plasma Mediated Ablation of Biological Tissues with Nanosecond-to-Femtosecond Laser Pulses: Relative Role of Linear and Nonlinear Absorption, IEEE Journal of Selected Topics in Quantum Electronics, vol. 2, No. 4, Dec. 1996, 9 pages.
Pace, E., et al, Fast Stable Visible-blind and Highly Sensitive CVD Diamond UV Photo Detectors for Laboratory and Space Applications, Diamond and Related Materials, vol. 9, Issues 3-6 (Apr.-May 2000) pp. 987-993.
Pandya et al (2015) Radiofrenquency ablation of pancreatic ductal adenocarcinoma: The past, the present and the future, World Journal of Gastrointestinal Oncology, Feb. 15, 2015, vol. 7, No. 2, pp. 6-11.
Papaioannou, Thanassis, et al., Excimer Laser Assisted Thrombolysis: The Effect of Fluence, Repetition Rate, and Catheter Size, Lasers in Surgery: Advanced Characterization, Therapeutics, and systems XII, Kenneth E. Bartels et al., Editors, Proceedings of SPIE vol. 4609 (2002), 6 pages.
Papaioannou, Thanassis, et al., Particulate debris analysis during excimer laser thrombolysis: An in-vitro study., Lasers in Surgery: Advanced Characterization, Therapeutics, and systems XII, Kenneth E. Bartels et al., Editors, Proceedings of SPIE vol. 4609 (2002), 9 pages.
Park, et al, Fluoroscopy-Guided Endovenous Foam Sclerotherapy Using a Microcatheter in Varicose Tributaries Followed by Endovenous Laser Treatment of Incompetent Saphenous Veins: Technocal Feasibility and Early Results, Dermatol Surg 2009, 35:804-812.
Partial European Search Report, EP19177412, Jul. 17, 2019, 1 page.
Pories and Albrecht (2001) Etiology of type II diabetes mellitus: role of the foregut. World J Surg 25(4): 527-31.
Pories et al., (2011) The surgical treatment of type two diabetes mellitus. Surg Clin North Am 91(4): 821-36.
Prince, M.R., et al, Preferential Light Absorption in Atheromas in Vitro—Implications for Laser Angioplasty, J of Clin Investigation, vol. 78(1) (Jul. 1986) pp. 295-302.
Proebstle, et al, Thermal Damage of The Inner Vein Wall During Endovenous Laser Treatment: Key Role of Energy Absorption by Intravascular Blood, Dermatol Surf 2002:28596-600.
Proebstle, et al, Treatment of the Incompetent Great Saphenous Vein by Endovenous RF Powered Segmental Therman Ablation: First Clinical Experience, Journal of Vascular Surgery, 2008, pp. 151-156.e1.
Richou, B, et al., Delivery of 10-mw Nd:YAG Laser Pulses by Large Core Optical Fibers: Dependence of the Laser-tensity Profile on Beam Propagation, Applied Optics, vol. 36, No. 7 (1997) pp. 1610-1614.
Ronkainen et al., (2005) Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 129(6): 1825-1831.
Ronkainen, Jukka, et al., Prevalence of Barrett's Esophagus in the General Population: An Endoscopic Study, Gastroenterology 2005; 129:1825-1831.
Rubino and Gagner (2002) Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 236(5): 554-559.
Rubino and Marescaux (2004) Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 239(1): 1-11.
Rubino et al, (2006) The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 244(5): 741-749.
Rubino et al., (2004) The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240(2): 236-42.
Schmedt, et al, Evaluation of Endovenous RF Ablation and Laser Therapy with Endoluminal Optical Coherence Tomography in an Ex Vivo Model, Journal of Vase Surg, 2007, pp. 1047-1058.
Schmidt-Uhling, T, et al, New Simplified Coupling Scheme for the Delivery of 20MW Nd:YAG Laser Pulses by Large Core Optical Fibers, Applied Physics B, Lasers and Optics, vol. 72, (2001) pp. 183-186.
Schwarz, et al, Endovenous Laser Ablation of Varicose Veins with the 1470-nm Diode Laser, Journal of Vase Surg vol. 51, No. 6, pp. 1474-1478. (2010).
Schwarzwälder and Zeller (2010) Debulking procedures: potential device specific indications. Tech Vasc Interv Radiol 13(1): 43-53.
Shangguan, HanQun, et al., Microsecond Laser Ablation of Thrombus and Gelatin Under Clear Liquids: Contact Versus Noncontact, IEEE Journal of Selected Topics in Quantum Electronics, vol. 2, No. 4, Dec. 1996, 8 pages.
Shuto, et al, Fiber Fuse Phenomenon in Step-Index Single-Mode Optical Fibers, IEEE Journal of Quantum Electronics, vol. 40, No., 8, 2004, pp. 1113-1121.
Sikorska and Pan (2004) The Effect of Waveguide Material and Shape on Acoustic Emission Transmission Characteristics, Part 1: Traditional Features. Journal of Acoustic Emission 22: 264-273.
Skorczakowski et al., (2010) Mid-infrared Q-switched Er:YAG laser for medical applications. Laser Physics Letters 7 (7): 498-504.
Smucler, et al, Invasive Leg Veins Treatment with 1064/1319 Nd:YAG Laser/Combination with Dye Laser Treatment, SPIE vol. 3590, pp. 78-87. (1999).
Supplementary European Search Report, EP15789895, Apr. 13, 2017, 2 pages.
Supplementary European Search Report, EP15796468, May 10, 2017, 2 pages.
Supplementary European Search Report, PCT/IB2014058688, Aug. 26, 2016, 7 pages.
Supplementary European Search Report, PCT/IL2012000088, Sep. 30, 2014, 8 pages.
Tabbara, et al, Laser-Fused Biologic Vascular Graft Anastomoses, Journal of Investigative Surgery, 6:3, 289-295. (1993).
Taylor, et al, Long Saphenous Vein Stripping Under Local Anaesthesia, Annals of the Royal College of Surgeons of England, 1981, vol. 63, pp. 206-207.
Taylor, Rod S., et al, Dependence of the XeCI Laser Cut Rate of Plaque on the Degree of Calcification, Laser Fluence, and Optical Pulse Duration, Lasers in Surgery and Medicine, vol. 10, Issue 5, (1990) pp. 414-419.
Topaz, On, M.D et al., “Optimally Spaced” Excimer Laser Coronary Catheters: Performance Analysis, Journal of Clinical Laser Medicine & Surgery vol. 19, No. 1, 2001, Mary Ann Liebert, Inc., pp. 9-14.
Verdam et al., (2012) An update on less invasive and endoscopic techniques mimicking the effect of bariatric surgery. J Obes 2012:597871, pp. 1-11.
Vuylsteke, et al, Intraluminal Fibre-Tip Centring Can Improve Endovenous Laser Ablation: A Histological Study, Eur J Vase Endovasc Surg, 2009, pp. 1-7.
Wang et al., (2013) Total transmission and total reflection of acoustic wave by zero index metamatehals loaded with general solid defects. Journal of Applied Physics 114(19): 194502, pp. 1-5.
Written Opinion of the International Searching Authority PCT/IL2017/050498; Mailed Sep. 10, 2017, 6 pages.
Written Opinion of the International Searching Authority, PCT/IL2012/000089, Jul. 13, 2012, 8 pages.
Written Opinion of the International Searching Authority, PCT/IL2014/058688, Jun. 15, 2014, 6 pages.
Written Opinion of the International Searching Authority, PCT/IL2015/050480, Oct. 21, 2015, 7 pages.
Written Opinion of the International Searching Authority, PCT/IL2015/050529, Sep. 16, 2015, 5 pages.
Written Opinion of the International Searching Authority, PCT/IL2017/050498, Nov. 9, 2017, 6 pages.
Related Publications (1)
Number Date Country
20230000555 A1 Jan 2023 US
Provisional Applications (2)
Number Date Country
61521523 Aug 2011 US
61446145 Feb 2011 US
Continuations (3)
Number Date Country
Parent 16436650 Jun 2019 US
Child 17930605 US
Parent 15649234 Jul 2017 US
Child 16436650 US
Parent 14001633 US
Child 15649234 US